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ABSTRACT 
 
ALEEZA J ROTH: Characterization of antigenic determinants and their correlation  
with disease activity in ANCA glomerulonephritis 
 (Under the direction of Dr. Ronald J. Falk, M.D.) 
 
This dissertation focuses on the interaction of antineutrophil cytoplasmic autoantibodies 
(ANCA) and two of their target autoantigens, myeloperoxidase and lysosomal membrane protein 2.  
The results of these interactions reveal novel epitopes associated with disease activity in 
granulomatosis with polyangiitis (GPA). 
The relationship between lysosomal membrane protein 2 (LAMP-2), a putative 3
rd
 
autoantigen, and ANCA disease is described in Chapter 1.  In 2008, LAMP-2 was purposed to be a 
novel autoantigen which predicted relapse in ANCA disease.  Exhaustive efforts uncovered that 
antibodies directed to LAMP-2 were not specific to ANCA disease nor were they relevant to disease 
activity in our US patient cohort.   
Chapter 2 investigates the binding sites of myeloperoxidase (MPO) specific autoantibodies in 
sera samples from patients with ANCA glomerulonephritis and healthy controls.  We prove that anti-
MPO autoantibodies are restricted to a limited number of epitopes on MPO and circulating 
autoantibodies target the same epitopes during relapse and remission.  In addition, to identify MPO 
epitopes of interest, a conformation dependent proteomics assay was used in conjunction with 
traditional immunologic methods.  An ANCA disease associated epitope was uncovered (Chapter 3) 
with an association with disease activity.  The discovery of this epitope has lead to the development 
of a pre-clinical test for ANCA disease.  As a whole, this is a comprehensive body of work which 
determines the complete profile of MPO specific epitopes found in a patient cohort in the 
southeastern US. 
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PROLOGUE: ANTIBODY MEDIATED AUTOIMMUNE DISEASE 
 
The existence of autoantibodies in autoimmune disease has been known for decades whereas 
the pathogenesis of autoantibodies in many autoimmune diseases has been debated.  There is 
evidence of pathogenecity both in vitro and in vivo
1-5
 in autoimmune diseases including: anti-GBM, 
systemic lupus erythematosus (SLE), type 1diabetes and antineutrophil cytoplasmic autoantibodies 
(ANCA) but the controversy of their role in pathogenicity persists.   One disease where the 
pathogenic role of autoantibodies has been largely accepted is anti-GBM disease (Goodpasture’s 
syndrome) where autoantibodies to the glomerular basement membrane were found in 1967 by 
Lerner et. al.  At that time, purified autoantibodies were transferred from a patient with anti-GBM 
disease to recipient monkeys and induced glomerulonephritis
1
.   Over the next 44 years, more and 
more evidence has supported this initial result and the pathogenesis of these autoantibodies has 
become central to the diagnosis and treatment of anti-GBM disease.   
In contrast, the discovery of anti-neutrophil cytoplasmic autoantibodies (ANCA) which are 
found in the circulation of patients with pauci-immune necrotizing and crescentic glomerulonephritis, 
less progress has been made. The most striking experiments have shown that ANCA are pathogenic 
in an MPO mouse model
5
.  A mouse model was developed by Xiao and colleagues using murine 
myeloperoxidase transferred into a myeloperoxidase knockout mouse and subsequent ANCA IgG 
derived from the knockout mouse are then transferred to an immune competent mouse.  After six days 
of the initial intravenous injection, all mice develop necrotizing glomerulonephritis which is 
strikingly similar to human disease
5
.  This MPO-ANCA mouse model strongly suggests the 
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pathogenic role of ANCA in mice.  Substantial evidence supports that MPO-ANCA and PR3-
ANCA cause granulomatosis with polyangiitis, however specific epitopes are unknown and it is only 
somewhat accepted that a restricted number of ANCA epitopes have pathogenic potential
4-6
.  Little is 
known about the specificity of disease-causing ANCA and moreover, whether the specificity of 
ANCA changes over the course of disease. This question has not been answered in GPA, or in many 
other antibody-induced autoimmune diseases.   
Autoantigens in ANCA disease 
There are two well characterized autoantigens ANCA target, myeloperoxidase (MPO) and 
proteinase 3(PR3).  In 2008, another autoantigen, lysosomal membrane protein 2 (LAMP-2), was 
implicated in GPA
7
.  All three proteins reside in human neutrophils and monocytes. 
In 1988, Carrlsson et. al. isolated and characterized h-LAMP-1 and h-LAMP-2 from chronic 
myelogenous leukemia cells.  LAMP-2 is a sialoglycoprotein and polylactosaminoglycan carrier 
protein which makes up 0.1-0.2% of total cell proteins
8
.  Polylactosaminoglycan are high molecular 
weight saccharides that are known to chaperone potentially antigenic molecules including, blood 
group antigens and tumor-associated antigens.  The sialoglycoprotein carriers of these saccharides are 
important to characterize because of their unique function.  LAMP-2 is a heavily glycosylated protein 
with both N and O-linked polysaccharides which in an aberrant form is thought to contribute to 
possible antigenicity in GPA
9
.  Interestingly, a nine amino acid sequence in the extracellular domain 
of the LAMP-2 protein (HGTVTYNGS) has complete homology to a gram-negative bacterial 
adhesion protein FimH.  FimH is a protein found in fimbriated bacteria such as E. coli and P. 
aeruginosa. 
Myeloperoxidase was first isolated and characterized as veroperoxidase in 1941 by Agner et. 
al.
10
  MPO is a 140kD heme containing enzyme found in myeloid cells and stored in the azurophilic 
granules of neutrophils and monocytes
11
.   It consists of a light chain and heavy chain comprising an 
asymmetrical dimer in vivo that’s main function is catalyzing reactions between hydrogen peroxide 
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and halides to perform its microbicidal role in the immune system
11, 12
.  MPO has one known 
inhibitor, ceruloplasmin (CP), which is a 150kD plasma protein and functions as an iron and copper 
transporter and also as an acute phase reactant.   MPO was first discovered to be the target of ANCA 
in 1988 by Falk et. al. in patients with systemic vasculitis and necrotizing and crescentic 
glomerulonephritis
13
.  Since that time autoantibodies targeting MPO have been utilized to diagnose 
and follow disease activity in patients with GPA. 
Lastly, proteinase 3 which is a 29kD serine protease, also found in the granules of neutrophils 
and monocytes, functions as an enzyme that is responsible for the cleavage of a variety of substrates.  
PR3 was identified as a target of ANCA in 1990 by Ludemann et. al. by immunoprecipitation with 
antibodies purified from patient’s sera14, 15.  PR3-ANCA is more prevalent in the Southwestern U.S. 
than MPO-ANCA and this serotype is associated with a higher frequency of relapse which correlates 
with anti-PR3 autoantibody titers
16
.  Williams et. al. characterized the presumed pathogenic epitopes 
of PR3 using linear peptide epitope mapping
17
. 
Autoantibody (ANCA) and autoantigen interaction 
Mapping the autoantigenic determinants of MPO and PR3 have been a much sought after 
area of research since the discovery of ANCA in an effort to glean information about the 
pathogenicity of autoantibodies.  Epitope specific ANCA have the potential to be precise tools to 
measure disease activity and pinpoint pathogenic mechanisms
18
.  Many groups studying ANCA 
disease have reported epitope targets of both MPO- and PR3-ANCA that are immunodominant in 
patients during active disease.  Initial efforts of epitope mapping PR3-ANCA were successful using 
overlapping peptides
17
, in stark contrast, epitopes on MPO were determined to be conformational
19
 
and remained an enigma.  Studies using overlapping MPO peptides that span the whole molecule 
have been either inconclusive or present conflicting results
20-24
.  To rectify a conformational 
conundrum, human/mouse chimeric molecules were used to preserve structure with broad 
unconvincing results
22
.  The most recent report on ANCA epitope specificity came from Bruner et. al. 
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who present seven immunodominant epitopes for consideration and suggest their probable influence 
on disease expression
20
.  The goal of epitope mapping MPO-ANCA is clear and the clinical and 
scientific benefits are far-reaching because of their potential role in pathogenesis. 
Presence of ANCA before clinical manifestation of autoimmune disease 
Understanding epitope specificity of natural autoantibodies in healthy subjects is equally 
important as disease specific epitopes. Olson et. al. present an intriguing article which describes the 
presence of asymptomatic autoantibodies (anti-GBM, PR3 and MPO) in healthy individuals years 
before onset of anti-GBM disease
25
.  Interestingly, the existence of autoantibodies found in healthy 
individuals is not a unique event.   This phenomenon has been well documented in several 
autoimmune diseases including SLE, ANCA glomerulonephritis, anti-GBM and type 1 diabetes
26-29
.  
As early as 1990, studies demonstrated the presence of  islet cell autoantibodies in healthy first-
degree relatives of  type I diabetes patients
30
.   Autoantibodies associated with type I diabetes are 
highly sensitive markers providing the ability to predict disease onset
27
.   More recently, in the case of 
SLE, an extensive article by Arbuckle et. al. described that 88 percent of patients studied who 
developed SLE had autoantibodies to at least one autoantigen while still clinically asymptomatic
26
.  
Further, the autoantibodies were measurable in multiple samples,  a mean of 3.3 years before 
diagnosis; with a significant accumulation of diverse autoantibodies leading up to clinical 
presentation of SLE
26
.  While asymptomatic autoantibodies are reported to be present and detectable 
in ANCA disease in patients before diagnosis; the final trigger for clinical manifestation of disease is 
unclear
28
. 
The most intriguing question in light of the presence of asymptomatic autoantibodies is: how 
does clinical manifestation of disease occur?  The nature of the glomerular basement membrane as an 
autoantigen gives clues to possible mechanisms.  Pedchenko et. al. characterized the delicacies of 
autoantibodies and the nature of the autoantigen recognized during active anti-GBM disease
31
.  There 
is an abundance of data demonstrating that anti-GBM disease autoantibodies are pathogenic and 
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specific to the autoantigenic region, but the autoantigen itself does not readily present the epitope.  A 
conformation-dependant epitope is known to be the primary pathogenic epitope which is exposed by 
disassociation of the endogenous hexamer structure
31
.  Understanding the development of how 
autoantibodies may develop in anti-GBM disease may provide clues for ANCA disease.  Since 
patients with GPA carry asymptomatic autoantibodies which are not pathogenic, their specificity for 
the autoantigen maybe the key to understanding the development of ANCA disease. 
Epitope mapping ANCA 
In a 2009 review on ANCA epitope specificity, the author relents that there is little known 
about MPO-ANCA and what is known about PR3-ANCA is limited 
32
.  What we do know is that 
MPO-ANCA are most likely directed towards conformational epitopes, favoring a cryptic epitope 
theory 
33
.  This is one of a number of theories of autoimmunity to explain the origins of GPA and 
possibly the reason for the ongoing cycle of relapse and remission characteristic of GPA.  Previous 
efforts to study ANCA and establish immunodominant MPO-ANCA epitopes provided minimal 
useful information, even when using chimeric molecules to preserve native structure 
22
.  It may be 
that natural or asymptomatic autoantibodies, present in the general population, play an active role in 
the development of pathogenic autoantibodies by disrupting autoantigen conformation.  Moreover, no 
epitope mapping study in ANCA disease has followed patients over time through remission and flares 
and neither MPO-ANCA titers or isotype class have proven to be good markers of relapse or 
remission 
34-37
.  This body of work addresses the issues present in the field today including: 
conformationally sensitive epitopes, natural and asymptomatic epitopes, patient epitope profiles over 
disease course, and clinical relevance.   It is essential to determine which ANCA have pathogenic 
potential and if an epitope specific autoantibody is required for disease onset.   
Central Hypothesis 
To summarize, ANCA interactions with myeloperoxidase, proteinase 3 and LAMP-2 are 
important in understanding GPA not just for pathogenesis but for diagnosis and treatment.  The 
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central hypothesis of this body of work is ANCA bind many sites on target autoantigens  and that 
these target epitopes are the same at disease onset and relapse while absent during remission.  In 
addition to the central hypothesis it encompasses several sub-hypotheses including 1) LAMP-2 is an 
autoantigen involved in GPA 2) Disease associated ANCA have pathogenic potential in vivo and in 
vitro 3) ANCA negative patients have autoantibodies to neutrophil proteins. 
In the following three chapters, this central hypothesis and subsequent sub-hypotheses will be 
addressed.  Chapter 1 describes our efforts to test the putative autoantigen LAMP-2, as a contributing 
factor in GPA.  A recombinant LAMP-2 protein and a synthetic LAMP-2 peptide were produced and 
used as substrates to determine if anti-LAMP-2 autoantibodies are prevalent in a Southeastern USA 
cohort of patients with PR3- and MPO-ANCA.  Detailed in Chapter 2, is the in depth method of 
epitope excision using mass spectrometry to test whether anti-MPO autoantibodies are restricted to a 
limited number of epitopes on MPO and whether circulating autoantibodies target the same epitopes 
during relapse.  Finally, in Chapter 3, we examine the question of ANCA negative glomerulonephritis 
and what autoantigen(s) and subsequent epitope is targeted in that population of patients.
 
_____________________________ 
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Chapter 1 
ANTI-LAMP-2 ANTIBODIES ARE NOT PREVALENT IN PATIENTS 
WITH ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODY 
GLOMERULONEPHRITIS 
 
 
 
This chapter consists of material from a manuscript reprinted with permission from J Am Soc 
Neph 2011
1
. 
 
In 2008, Kain et.al. reported a novel autoantigen found in ANCA disease.  This autoantigen was 
lysosomal membrane protein 2 or LAMP-2 and was putatively found in 93% of sera from patients 
with pauci-immune focal necrotizing glomerulonephritis in Vienna, Austria.  This chapter focuses on 
the investigation of anti-LAMP-2 autoantibodies in sera from the Glomerular Disease Collaborative 
Network at UNC Chapel Hill. 
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Lysosomal membrane protein 2 (LAMP-2) is a target of antineutrophil cytoplasmic 
autoantibodies (ANCA) in addition to the more commonly known targets proteinase 3 and 
myeloperoxidase.  The prevalence of anti-LAMP-2 antibodies and their relationship to disease in 
ANCA glomerulonephritis are not well described.  We measured anti-LAMP-2 reactivity in 278 sera 
samples from patients with ANCA glomerulonephritis (n=103); those with fimbriated, gram–negative 
Escherichia coli urinary tract infection (n=104); disease controls (n=19); and healthy volunteers 
(n=52).  With levels in healthy controls used to define a reference range, anti-LAMP-2 reactivity was 
present in 21% of ANCA sera; reactivity was also present in 16% of the control group with urinary 
tract infection.  Western blotting and immunofluorescence microscopy did not verify positivity.  
There was no correlation between anti-LAMP-2 antibodies and disease activity.  Furthermore, Wistar 
Kyoto rats injected with anti-LAMP-2 antibodies did not develop glomerulonephritis.  In conclusion, 
antibodies that react with LAMP-2 may exist at very low titers in a minority of patients with ANCA 
disease.  These data do not support a mechanistic relationship between anti-LAMP-2 antibodies and 
ANCA glomerulonephritis. 
Introduction 
In 1995, Kain and coworkers reported that lysosomal membrane protein 2 (LAMP-2) is a 
target of anti-neutrophil cytoplasmic autoantibodies (ANCA) in addition to proteinase 3 (PR3) and 
myeloperoxidase (MPO).
7
  Recently, Kain and coauthors further characterized LAMP-2 
autoantibodies and concluded that more than 90% of patients with active pauci-immune 
glomerulonephritis had circulating anti-LAMP-2 autoantibodies.
9
  The majority of these patients also 
had MPO-ANCA and PR3-ANCA.
15, 38-42
 These findings have had a significant impact on both the 
clinical and research communities.
43-45
  Intriguingly, anti-LAMP-2 antibody epitope analysis 
indicated the antibodies recognized a nine-amino acid peptide in a bacterial adhesion protein (FimH) 
carried by fimbriated, gram-negative bacteria, including Escherichia coli.
9
  An immunological 
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response triggered by bacterial infection led to production of autoantibodies to the human LAMP-2 
protein.
9
  The resulting anti-LAMP-2 autoantibodies were proposed to be pathogenic and able to 
cause glomerulonephritis in rats.  Rats immunized with FimH peptide developed pauci-immune 
glomerulonephritis and antibodies to human LAMP-2.
9
  If fimbriated bacteria, with the relevant 
amino acid sequence of FimH, are proven to trigger ANCA disease in susceptible individuals the 
therapeutic implications could be far-reaching.   
The purported high prevalence of anti-LAMP-2 autoantibodies stimulated discussions on 
whether a routine screen for anti-LAMP-2 autoantibodies should be initiated for all ANCA-disease 
patients.  Before such steps are taken, their prevalence and their relationship with disease activity 
should be established in independent cohorts. To establish the diagnostic value of anti-LAMP-2 
antibodies, the specificity and sensitivity of the antibody must be verified in multiple patient cohorts 
evaluated in multiple laboratories. We present data generated at the UNC-Kidney Center, NC, USA.  
LAMP-2 antibodies are not prevalent in patients with MPO-ANCA, PR3-ANCA and ANCA negative 
glomerulonephritis. 
Materials and Methods 
To test for the presence of LAMP-2 autoantibodies in patients with pauci-immune 
glomerulonephritis we chose a cohort of 103 patients with biopsy-proven disease comprised of 53 
females and 50 males; 48 MPO, 53 PR3, 2 both MPO and PR3 patients with a median age of 53 ± 
18.6 years.  Birmingham Vasculitis Activity Score or BVAS, which is the measurement of disease 
activity in vasculitis patients, was used upon chart review to cumulatively define disease status of the 
patient cohort.  As determined by BVAS, 45 of these patients had active disease (BVAS ˃0) while 57 
were in remission (BVAS =0).  For healthy control populations we tested 52 healthy individuals as 
well as 104 patients with urinary tract infections.   
Protein, Peptides, and Antibodies 
For the recombinant protein, the extracellular domain of LAMP-2 was amplified by PCR 
corresponding to AA (1-359) and cloned into a pcDNA2.1 His-Tag plasmid construct (Invitrogen, 
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Carlsbad, CA) modified with a BM40 secretion signal. Protein was produced using the HEK-293F 
expression system (Invitrogen). Protein from HEK-293F cell supernatant was purified using a His-
Trap Column (GE Healthcare, Piscataway, NJ) by FPLC. The LAMP-2 epitope (41-49) peptide and 
the FimH peptide were synthesized (331-341). A rabbit was immunized with the LAMP-2 peptide to 
produce high titer anti-LAMP-2 total IgG for rat studies. For assay positive controls we used a 
commercial polyclonal antibody raised against native full length LAMP-2 (Abnova, Taipei City, 
Taiwan).   
ELISAs and Westerns 
For the recombinant protein ELISA LAMP-2 was coated on a Costar 96-well high binding 
EIA/RIA plate (Corning, Lowell, MA) at 4°C overnight (10µg/mL), blocked for 2 hours in 3% BSA  
(ThermoFisher Scientific, Waltham, MA), and probed with patient serum at 1:20 in 1% BSA. 
Reactive IgG was detected by alkaline-phosphatase conjugated goat anti-human IgG antibody 
(Jackson ImmunoResearch Labs, West Grove, PA). Optical density at 405 nm was measured using a 
VERSAmax tunable microplate reader (Molecular Devices, Sunnyvale, CA). For the LAMP-2 and 
FimH peptide ELISAs, the peptides were first crosslinked on themselves to enhance plate binding 
using 10% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) in PBS (Invitrogen) at a concentration 
of 5mg/mL for two days at room temperature. Nunc Polysorp plates (ThermoFisher Scientific) were 
then irradiated for 20 minutes in a UV Stratalinker (Stratagene, La Jolla, CA) and coated with 
crosslinked peptide overnight at 4°C (50µg/mL). The proceeding steps of the protocol were carried 
out the same as in the rLAMP-2 ELISA above. Westerns were used to confirm positives on the 
recombinant ELISA by probing with serum in 1% blotto at 1:100 overnight (4°C) on 10µg of 
rLAMP-2 antigen and MPO (Elastin Products Company, Owensville, MO) or recombinant PR3, 
depending on the patient's diagnosis.  
Immunofluorescence Microscopy Assays 
A cytospin was used to mount HEK-293F cells (Invitrogen) transfected with LAMP-2 onto 
microscope slides (ThermoFisher Scientific). Cells were fixed using acetone (ThermoFisher 
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Scientific) and were probed with patient serum at 1:100 for 1 hour. Bound IgG was detected by 
immunofluorescence microscopy using FITC conjugated goat anti-human IgG (Jackson 
ImmunoResearch). LAMP-2 transfected O-linked glycosylation deficient CHO-LDL-D cells were 
also used as a substrate. CHO LDL-D cells (ATCC, Manassas, VA) were obtained with the 
permission of Dr. Monty Krieger. Cells were grown in varying conditions to alter the glycosylation 
pattern of the recombinant LAMP-2. To knock out O-linked glycosylation, cells were grown in Ham's 
F12 medium (Invitrogen) supplemented with 5% FBS (Invitrogen) and 1% Penicillin-Streptomycin 
(Invitrogen). For fully glycosylated LAMP-2, 20µM galactose and 200µM N-acetylgalactosamine 
(Sigma-Aldrich) was added to the O-linked knock out medium. To knock out both forms of 
glycosylation, cells were grown in 50% OPTI-MEM, 47% alpha-MEM, and 3% dialyzed FBS 
(invitrogen)(personal communication). CHO cells were grown on 8-well CC-2 treated microscope 
slides (ThermoFisher Scientific) to 70% confluence and were fixed with 4% paraformaldehyde, 
permeabilized with pure methanol at -20°C (ThermoFisher Scientific) for 10 minutes, and blocked 
with 5% goat serum in 0.05% triton X-100 (ThermoFisher Scientific).  Patient Serum was diluted at 
1:100 and FITC conjugated goat anti-human was used to detect bound IgG. The INOVA diagnostics 
ANCA immunofluorescence kit was used to stain human neutrophils with a polyclonal rabbit anti-
human LAMP-2 antibody (Abnova) at 1:100. The primary antibody was the only reagent not found in 
the kit, the method from the kit was used exactly.  Dr. J. Charles Jennette reviewed all 
immunofluorescence slides using an Olympus BX41 fluorescence microscope.  
In-vivo Testing of LAMP-2 Antibody Pathogenicity   
Total IgG was purified from rabbit serum using a Hi-Trap Protein G column (GE Healthcare) 
using a FPLC. WKY rats were obtained from Harlan Sprague Dawley age and weight matched at 
about 80g.  10mg anti-LAMP-2 high titer total IgG or normal rabbit IgG was transferred by tail vein 
injection into rats (5 rats per group). Rats were sacrificed after five days and kidneys were harvested 
for histological analysis, fixed in formalin, embedded in paraffin, sectioned and stained with H&E 
and PAS stains. To ensure successful transfer of rabbit IgG, serum was obtained 24 hours after 
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transfer and coated on a Costar 96 well high-binding EIA/RIA plate overnight at 4°C and blocked 
with 3% BSA for 1 hour. Bound IgG was detected using alkaline-phosphatase conjugated goat anti-
rabbit IgG (Jackson ImmunoResearch).  Urines were collected on days 0,1,3 and 5 and urinalysis 
performed with chemstrip 10 MD urinetest strips (Roche).  Antibodies to LAMP-2 were produced in 
a New Zealand White rabbit (Robinson services) by immunizing with LAMP-2 peptide 
(HGTVTYNGS) in Freund’s complete adjuvant; subsequent boosts were in incomplete Freund’s 
adjuvant.  A Rat-ANCA test was performed on a rat total leukocyte preparation from healthy rats.  
Total leukocytes were put onto slides using a cytospin and stained with a positive control LAMP-2 
antibody produced in a rabbit (Sigma) at a concentration of 1:100.  Rabbit total IgG, pre-immune and 
post immunization with LAMP-2 peptide (HGTVTYNGS) was purified from sera with sepharose 
protein A/G beads (Santa Cruz Biotechnologies) and used at 3mg/mL followed by a goat anti-rabbit 
FITC conjugated secondary (Jackson Immunology) at 1:200.  All slides were reviewed by J. Charles 
Jennette. 
Results 
Comparison of LAMP-2 protein substrates used for antibody detection  
LAMP-2 (lysosomal-associated membrane protein 2) is normally produced in all cell types. It 
contains oligosaccharide chains, some of which are polylactosaminoglycans, which are species 
specific, complex.  These are dispersed on two domains of the protein separated by a hinge-like 
structure containing O-linked oligosaccharides (Fig.1.1A).
46
   
A recombinant LAMP-2 protein consisting of the entire extracellular domain
( aa 1-350) 
was 
utilized as substrate for studies at the UNC-Kidney Center. The cDNA of human LAMP-2a was 
subcloned into a mammalian expression vector omitting the N-terminal signal sequence, the 
membrane spanning domain, and the cytoplasmic tail (Fig.1.1B). Recombinant protein was expressed 
in Human Embryonic Kidney Cells (HEK) to make possible human-specific protein glycosylation.  
Affinity purified protein was of high quality as determined by SDS-PAGE (Fig. 1.1C) and was 
recognized by a commercial, polyclonal anti-LAMP-2 antibody by western analysis (Fig. 1.1D).  In 
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addition a synthetic peptide was synthesized locally which contained the amino acids identified as the 
FimH-like epitope (Fig. 1.1E). Purity of FPLC-eluted peptide was indicated by a single peak (Fig. 
1.1F) and peptide composition confirmed by mass spectrometry (Fig. 1.1G). 
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Figure 1.1 Substrates used to detect anti-LAMP-2 antibodies in human sera 
 
 
Figure 1.1  LAMP-2  protein and peptide substrates used to screen for LAMP-2 reactivity in sera.  (A) 
Schematic of full length human LAMP-2a protein denoting O-linked hinge region and N-glycosylation sites 
(adapted from Fukuda et al, 1988). (B) Sites of putative pathogenic epitopes are designated in yellow boxes 
(HGTVTYNGS) (QGKYSTAQDC). For studies at UNC-Kidney Center, LAMP-2a cDNA was subcloned 
omitting the C-terminal transmembrane domain (T-M) and cytoplasmic tail. (C) Analysis of recombinant 
protein produced in HEK cells indicated high purity as assessed by SDS-PAGE .  (D) Recombinant protein was 
recognized by purchased hLAMP polyclonal antibody, assessed by western blot . (E) Peptide utilized in studies 
at UNC-Kidney Center. (F) Purity of FPLC-eluted HGTVTYNGS peptide was indicated by a single peak. (G) 
Confirmation of peptide composition by mass spectrometry indicated correct mass of 934.943. (H) Schematic of 
LAMP-2 protein utilized in Mass. General studies produced in wheat germ extract system.  
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Table 1.1 Description of sera samples 
 
 
Source Number Samples Analyzed Description of Sample 
Local North Carolina 
Community 
52 Healthy controls  
UNC Kidney Center 103 *ANCA 
Pauci-immune focal necrotizing 
glomerulonephritis from GDCN 
consortium 
  MPO-ANCA   (n=48) 
  PR3-ANCA   (n=53) 
  MPO and PR3 positive  (n=2) 
  † Active   (n=45) (BVAS > 0) 
  Remission   (n=57) (BVAS =0) 
  New Onset  (n=15) 
Samples collected at disease onset 
prior to medication 
  Never frozen (n=10) 
Serum obtained and immediately 
assayed, untreated and treated active 
disease patients. 
  
   
  
   
UNC Hospitals 
Mclendon Clinical 
Laboratories 
104 Urinary Tract Infection Otherwise healthy individuals 
clinically diagnosed with a FimH 
positive bacterial infection 
   
UNC Kidney Center 10 SLE disease control from GDCN consortium 
Medical University of 
Vienna 
9 FNGN 
Pauci-immune focal necrotizing 
glomerulophritis provided by  
Kain et al. 
 
  Positive per Kain et al. (n=4) 
  Negative per Kain et al. (n=5) 
*ANCA samples are divided into MPO, PR3 or dual positive; active or remission.  New 
Onset and Never frozen samples are included into the total number of samples. 
† One patient from the test cohort had insufficient data to determine disease activity. 
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A recombinant LAMP-2 protein commercially-produced in a Wheat Germ Cell free system 
was utilized as substrate in studies conducted at Massachusetts General Hospital.  Protein that 
translated this system is non-glycosylated and thus the LAMP-2 substrate can be likened to the one 
“bacterially” produced and utilized by Kain et al.9  The amino acid sequence is only a portion of the 
extracellular domain
(aa 30 -127)
, but does contain the FimH-like epitope (Fig. 1.1H).  An all-inclusive 
listing of sera samples analyzed in these studies is provided in Table 1.1.  A total of 680 samples were 
screened for reactivity against LAMP-2.   
Sera from patients with PR3-ANCA or MPO-ANCA have little to no reactivity to rLAMP-2 
protein produced in HEK cells 
Kain and coworkers from the Medical University of Vienna graciously provided the UNC-
Kidney Center with sera samples (n=9) consisting of four known positives for LAMP-2 antibodies in 
their assay system and five known negatives.  In our assay system, four were positive and five 
negative against HEK-expressed rLAMP-2 (Fig. 1.2A), providing confidence that the systems were 
comparable.  We found that, of the UNC-ANCA disease patient group (n=103), 21.1% were deemed 
positive for reactivity against rLAMP-2 in this assay (>mean plus 2SD of healthy controls) (p=0.004) 
by (Fig. 1.2A). Sera from otherwise healthy individuals with active urinary tract infections (UTI) 
(n=104), and producing antibodies against the gram-negative bacteria, contained antibodies reactive 
against rLAMP-2 at a frequency similar to that found in the ANCA disease group (p=0.097). Samples 
from patients considered to have “new-onset” disease were obtained either prior to therapy (n=7) or 
immediately after the first dose of glucocorticoids (n=9).  Open boxes in the ANCA disease cohort 
signify patients during active disease with a BVAS>0 (Fig. 1.2A).   Sera from SLE patients were 
negative for rLAMP-2 reactivity (Fig. 1.2A).  rLAMP-2 reactivity was not significantly associated 
with disease onset nor with fresh sera (tested the same day is was drawn - never frozen).   
As with most clinical testing, a second assay was employed to validate ELISA results. All 
samples reactive with rLAMP-2 (n=26) were tested by western blot analysis.  MPO-ANCA positive 
sera that were also positive for rLAMP-2 by ELISA were negative for LAMP-2 by western blot (lane 
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1- Fig. 1.2B), meanwhile they were reactive with native MPO (lane 2).  Blot 1 was re-probed with a 
commercially available anti-LAMP-2 antibody to verify that rLAMP-2 was present in lanes loaded 
with the protein preparation. PR3-ANCA sera and sera samples provided by Kain et al were also 
negative for rLAMP-2 reactivity by western analysis (data not shown).   
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Figure 1.2 Sera reactivity against recombinant LAMP-2 protein by ELISA and Western blot 
 
Figure 1.2 Seroreactivity against recombinant LAMP-2 protein produced in HEK293 cells. (A) ELISA results 
indicate a subgroup of ANCA patients’ sera samples were reactive against rLAMP-2 protein, compared to 
healthy controls, UTI, SLE, ANCA sera from Kain et. al. new onset and never frozen sera (solid bar indicate 2 
SD above the mean of healthy controls).  In the ANCA disease group open squares indicated “Active” disease 
and ‘filled diamonds’ are patients in remission; in the new-onset group ‘asterisks’ indicate samples collected 
prior to steroid treatment (B) Evaluation of  serum reactivity by western blot analysis (M –size marker; Lane1 –
1ug purified rLAMP-2; 1ug native MPO).  MPO-ANCA –positive samples that were also reactive with rLAMP-
2 by ELISA did not react with rLAMP-2  (Lane1) but did react with  MPO protein (Lane 2).  Blot 1 was re-
probed with a commercial polyclonal anti-LAMP-2 antibody to verify rLAMP-2 protein loading on the gel.  
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Reactivity against rLAMP-2 by indirect immunofluorescence microscopy 
A third assay was employed (IFA) in effort to validate positive rLAMP-2 reactivity. rLAMP-
2 protein, over-expressed in HEK cells, stains with a polyclonal anti-LAMP-2 antibody to produce a 
cytoplasmic staining pattern consistent with preferential staining of lysosomes (Fig. 1.3A right panel).  
Low levels of endogenous LAMP-2 protein were detected in non-transfected cells (Fig. 1.3A left 
panel).  None of the healthy controls (n=52) or ANCA disease sera (n=103) produced a staining 
pattern similar to the positive control staining, although some samples had low intensity staining with 
other patterns.  SLE samples (n=10) often stained cells in a variable, sometimes nuclear, pattern.  
Representative samples are shown in Figure 1.3B of two healthy controls (one with non-specific 
staining), two disease controls showing nonspecific reactivity (SLE) and four high-titer ANCA 
disease sera. One MPO-ANCA shows an irregular punctuate staining similar to control samples and 
differing from the polyclonal anti-LAMP-2 control. Many SLE samples had varying patterns of 
nuclear staining apparently caused by anti-nuclear antibodies, but none had staining resembling the 
anti-LAMP-2 positive control. 
It was reported that heavy glycosylation of rLAMP-2 produced in HEK cells could alter 
antigenicity.
9
  To address this issue, we acquired the same cell line utilized in studies by Kain et al, 
which is O-linked glycosylation deficient (CHO-LDL-D cells) and performed IFA on rLAMP-2 
overexpressing CHO-LDL-D cells.  We could not detect reactivity to this substrate (Fig. 1.3C).  
Further, cells were grown in varying conditions to alter the glycosylation pattern of the over-
expressed rLAMP-2 protein. O-linked glycosylation deficient cells were grown in regular culture 
medium (alpha-MEM) without additives to produce protein without hinge region O-linked 
glycosylation.  Manipulation of rLAMP-2 produce in CHO-LDL-D did not produce seropositivity 
(data not shown). Three sera reacted to the non-transfected CHO-LDL-D cells (Fig. 1.3D). 
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Figure 1.3 Sera reactivity against recombinant LAMP-2 protein by indirect immunofluorescence (IF) 
 
Figure 1.3 Immunofluorescence assays (IFA) using cell lines transfected with rLAMP-2. (A) Polyclonal anti-
LAMP-2 antibody (but not negative control antibody) produced low level staining in nontransfected human 
embryonic kidney cells (HEK) consistent with staining of low level endogenous LAMP-2 protein (left panel) 
whereas HEK cells transfected with LAMP-2 produced intense cytoplasmic staining (right panel).  (B) None of 
the healthy controls (n=52) or ANCA disease sera (n=103) produced a staining pattern similar to the positive 
control staining, although some samples had low intensity staining with other patterns.  SLE samples (n=10) 
often stained cells in a variable pattern, including nuclear staining consistent with anti-nuclear antibodies, but 
none stained with a pattern similar to the positive control. Representative staining patterns, including low 
intensity staining that did not correspond to the positive control pattern are shown for two healthy controls 
(Normal), two SLE controls (SLE) and four high-titer ANCA disease sera. Note that one MPO-ANCA shows an 
irregular punctuate staining similar to control samples, but no samples resembled the positive control. (C)  IFA 
using rLAMP-2 overexpressing O-linked glycosylation deficient cells (CHO-LDL-D cells) generously provided 
by Kain et al. Positive control anti-LAMP-2 antibodies produced intense cytoplasmic staining (left two panels) 
but ANCA-positive patient sera produced no staining (right panel). (D) IFA was performed on CHO-LDL-D 
cells grown in varying conditions to alter the glycosylation pattern of over-expressed rLAMP-2 protein. Of the 
103 samples, 3 reacted to the transfected and non-transfected CHO-LDL-D cells, and the pattern did not 
resemble the positive control. 
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Reactivity against LAMP-2 synthetic peptide 
We produced a synthetic peptide of the pathogenic epitope (HGTVTYNGS) identified by 
Kain et al. (Fig. 1.4). Sera were tested for reactivity by peptide-ELISAs.  Sera from regional healthy 
controls were highly reactive raising the threshold for positivity to an OD value of 1.03 (mean plus 
2SD of healthy control). Only 4% of ANCA disease samples had results >1.03, which was not 
statistically significant (Fig. 1.4).  UTI, SLE and nine samples from Kain et al were not significantly 
different from healthy controls.  Positivity was defined as two standard deviations above the mean of 
the healthy controls (1.04). The four positive samples in the total ANCA disease group were all new 
onset. 
Injection of high titer rabbit anti-hLAMP-2 antibodies did not cause glomerulonephritis in 
WKY rats 
To support the hypothesis that LAMP-2 autoantibodies are causal in human disease, Kain et 
al. demonstrated that injection of antibodies raised against the LAMP-2 peptide in a rabbit caused 
crescentic glomerulonephritis in WKY rats.
9
  We attempted to reproduce these results.  Total IgG 
from a LAMP-2-peptide (HGTVTYNGS) immunized rabbit was highly reactive with rLAMP-2 
protein, LAMP-2 peptide and cross-reactive with FimH peptide (Fig. 1.5A).  IgG from the immunized 
rabbit was reactive with rat leukocytes by immunoflourescence but the preimmune serum from this 
rabbit was not (data not shown).  Animals were injected with normal rabbit-IgG (n=5) or with rabbit 
IgG reactive against human LAMP-2 peptide (n=5).  Post-injection (24hrs) circulating rabbit-specific 
IgG was detected in the five rats immunized with anti-LAMP-2 IgG (Fig. 1.5B).  Urines were 
examined days one, three and five (Fig. 1.5C) and none of the rats developed hematuria, proteinuria 
or leukocyturia. Histological examination of tissues (by JCJ) revealed no histologic abnormalities, 
including no glomerulonephritis.   
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Figure 1.4 Sera reactivity against LAMP-2 synthetic peptide 
 
Figure 1.4  Sera reactivity against LAMP-2 peptide (HGTVTYNGS) by ELISA.  Positivity was defined as two 
standard deviations above the mean of the healthy controls (1.04). The four positive samples in the total ANCA 
disease group were all new onset. 
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Figure 1.5 Transfer of anti-LAMP-2 peptide antibodies to WKY rats 
 
Figure 1.5 Transfer of anti-LAMP-2-peptide antibodies into rats did not cause glomerulonephritis. (A)  
Characterization of anti-LAMP-2 antibodies generated in a rabbit for transfer into WKY rats. Antibody strongly 
reacts with LAMP-2 peptide with some cross-reactivity to FimH peptide. (B) Circulating rabbit IgG detected in 
rats one day post-injection. (C) Five days post-injection there was no detectible hematuria or proteinuria.  
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Figure 1.6 Staining patterns of anti-LAMP-2 antibodies on human neutrophils 
 
 
Figure 1.6  LAMP-2 stain human neutrophils with a cytoplasmic pattern (A) Normal Human Neutrophils 
stained with PR3-ANCA patient’s serum (B) Normal Human Neutrophils stained with monoclonal anti-LAMP-
2 antibody. 
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Comparison LAMP-2 titers with PR3-ANCA and MPO-ANCA titers in dual positive sera 
staining pattern of anit-LAMP-2 antibodies on human neutrophils 
If anti-LAMP-2 antibodies coexist in patients’ sera with PR3- and MPO-ANCA as reported,9 
how would they affect the results of a routine clinical Immunofluorescence assay?   anti-LAMP-2 
monoclonal antibody stained human neutrophils with a cytoplasmic pattern (Fig. 1.6A) while normal 
human neutrophils stained with PR3-ANCA patient’s serum (Fig. 1.6B) showed a similar cytoplasmic 
staining pattern.  
Discussion 
To examine the frequency of anti-LAMP-2 antibodies associated with ANCA 
glomerulonephritis in a USA cohort, sera was obtained from patients at the UNC-Kidney Center, 
North Carolina. 
Approximately 22.8% of PR3-or MPO-ANCA positive sera were also reactive with LAMP-2 
by ELISA. However, by western blotting and immunofluorescence staining of HEK cells, LAMP-2 
positivity could not be validated.  Our cohort consisted of about half with active disease and half in 
remission and there was no significant difference in the incident of LAMP-2 seroreactivity between 
the groups.  
It was reported that antibodies against bacterial protein FimH were cross-reactive with human 
LAMP-2 protein and that, through molecular mimicry, bacterial infections could contribute to the 
development of ANCA disease. We tested sera from individuals with gram-negative bacteria urinary 
tract infections, who were otherwise healthy and negative for PR3- or MPO-ANCA, and found that 
approximately 16% were reactive with LAMP-2 protein.  Dr. Kain and colleagues reported that 9/13 
patients with pauci-immune glomerulonephritis had a diagnosis of infection with FimH-expressing 
bacteria prior to presentation, and that these patients had antibodies that bound the region of LAMP-2 
that contained amino acid sequence homologous to FimH.  We synthesized a peptide containing the 
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FimH-like sequence of LAMP-2 and screened sera for reactivity.  Results indicated that both healthy 
controls and patients had similar reactivity.   
Recombinant LAMP-2 proteins were utilized as substrates for analyses presented here: one 
produced in a human embryonic kidney cell line, which post-translationally adds glycosylation 
moieties to the protein.  To address the possibility that the LAMP-2 recombinant proteins utilized in 
our experiments were not optimal in detecting LAMP-2 reactivity, we obtained the glycosylation-
deficient Chinese hamster cell line, utilized in studies by Dr. Kain and colleagues, and screened for 
sera reactivity to overexpressed human LAMP-2 protein. By manipulating the culturing conditions, 
we could assess various glycosylation states and their effect on sera reactivity to LAMP-2 by 
immunofluorescence staining.  All samples were negative under all conditions when compared to the 
staining pattern of a commercially available LAMP-2 antibody.   
To explore the pathogenic potential of anti-LAMP-2 antibodies, WKY rats were injected with 
anti-LAMP-2 antibodies produced by immunizing a rabbit with the pathogenic peptide.  Histologic 
evaluation indicated no evidence of renal disease in injected animals, in contrast to what was 
previously reported.  We acknowledge that factors such as the supplier of the particular strain of 
WKY rats, housing and food in the UNC animal facility may have influenced the susceptibility.   
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Table 1.2 Characteristics of patient cohort with LAMP-2 reactivity 
  
 
Categories compared 
Reactivity against 
recombinant LAMP-2  
 Reactivity against LAMP-2  
peptide (P41-49) 
 
Percent 
Positive (%) 
P value*  
Percent 
Positive 
(%) 
 
P value* 
BVAS vs LAMP-2 reactive  0.1465   1.0000 
 Active 28.9   4.7  
 Remission 15.8   3.5  
ANCA Titer vs LAMP-2 reactive‡      
 PR3 ANCA 22.0 0.2323    
 MPO ANCA 24.4 0.4129    
ANCA phenotype† vs LAMP-2 
reactive 
 1.0000   1.0000 
 c- ANCA seropositive 23.1   3.8  
 p- ANCA seropositive 21.7   2.3  
Disease type vs LAMP-2 reactive  0.4680   0.13 
 Renal Limited 13.3   0.0  
 Microscopic polyangiitis 22.7   7.5  
 Granulomatosis 20.0   2.6  
 Others§ 50.0   0.0  
Disease Status vs LAMP-2 reactive  0.0842   0.0003 
 New Onset 40.0   36.0  
 Ongoing Disease 18.2   0.0  
Male  vs. Female for number of 
positives 
     
 Positive ANCA patients 10.2 vs 31.5 0.0148  6.0 vs 2.1 0.6193 
 Positive UTI patients 15.0 vs 11.8 0.7097  0.0 vs 21.0 0.0008 
% Positive = percent of individuals with OD values 2SD above the mean of healthy controls 
 *P values were calculated by Fisher’s Exact Test 
‡ P value was calculated using Wilcoxon two sample test 
† Three patients from the test cohort were excluded for this analysis due to insufficient serotype data. 
§ Four patients were placed in this category due to insufficient clinical data. 
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Similar to Dr. Kain and colleagues,
9
 we found that individuals with a fimbriated bacterial 
infection may produce antibodies reactive with LAMP-2.   However, we did not find the frequency of 
anti-LAMP-2 positive sera in the ANCA glomerulonephritis group that was described previously.  
There are a number of reasons to explain the differences. The most obvious disparity is geographical 
differences in the patient cohorts.  A second explanation is that our reagents and methodologies are 
not the same as those of Kain et al even though every effort possible was made to duplicate their 
results, including using sera they provided as controls.  Moreover, we exchanged unidentified sera 
samples to test the concordance between our assay and the one used in Dr. Kain’s group and the 
overall results were similar.  There was some discordance on sample to sample comparisons, but this 
did not exceed what would be expected when comparing assays that are not optimized.  
In conclusion, the mechanistic association between fimbriated, bacterial infections and 
ANCA disease has exciting appeal but we have not been able to confirm the evidence for this.  We 
find very low titers of anti-LAMP-2 antibodies in human sera, although there was no difference 
comparing healthy individuals with gram-negative bacterial infections, ANCA negative GN sera and 
MPO-ANCA, or PR3-ANCA positive sera. There was no correlation with disease activity or across 
demographics (Table 1.2).  We conclude that anti-LAMP-2 antibodies are identifiable, low titer, 
natural or induced antibodies occasionally found in the population.
 
 
 
 
  
Chapter 2 
AUTOANTIGENIC DETERMINANT PROFILING IN 
MYELOPEROXIDASE-ANCA DISEASE 
 
Granulomatosis with polyangiitis (GPA) is the most common form of aggressive glomerular 
disease and is associated in most cases with a systemic necrotizing vasculitis. ANCA have been found 
to be markers of disease since 1985 and more recently have been found to be pathogenic in vivo
5
. 
Patients with ANCA disease have a polyclonal response to ANCA autoantigens myeloperoxidase 
(MPO) and proteinase 3 (PR3). ANCA titers correlate with disease activity in some patients 
(primarily in PR3-ANCA), while the majority of MPO positive ANCA patients exhibit a poor 
correlation of ANCA titer with disease activity. In this study we analyze MPO-ANCA samples from 
66 unique patients to determine the diverse epitope landscape of ANCA disease.   We utilized matrix 
assisted laser desorption/ionization time of flight mass spectrometry (MADLI-TOF/TOF MS) to 
identify a region of where antibodies bind to antigens which is inherently the antigenic epitope.  
Further, enzyme-linked immunosorbent assays were used to verify seroreactivity to identify linear 
epitopes.   Healthy subjects and ANCA disease patients share a handful of anti-MPO specific 
autoantibodies; these autoantibodies do not have pathogenic potential. In patients with MPO-ANCA 
disease, two disease associated epitopes were found to be linear and correlate to disease activity. 
Since MPO-ANCA manifests in such a diverse clinical course; genetics, environment but also 
specificity of autoantibodies likely contribute to the pathogenicity of disease.  
Introduction 
Protein-protein interactions have primarily been studied in depth using mass spectrometry 
and x-ray crystallography, more recently these techniques have been applied to human pathology and 
immunology.  Several proteomics approaches have been developed in search of disease biomarkers 
and therapeutic targets with varying success
47
.  Interactions between autoantibodies and autoantigens 
30 
 
are in essence protein-protein interactions, which are highly sensitive to the microenvironment of the 
human body particularly in autoimmune disease.  Methods utilizing proteomics strategies take into 
consideration: 3-dimensional conformation, microenvironment, kinetics and fluidity
48
.  In many 
autoimmune clinical assays, sheer quantity of autoantibodies may not be specific enough to determine 
disease activity.  In MPO-ANCA disease a focus on individual autoantibody epitope specificity could 
be a more accurate measure of disease activity.   
Patients diagnosed with MPO-ANCA are known to have a polyclonocal response to MPO 
and their titers are currently followed throughout their disease course to glean information about 
disease activity
49, 50
.  Total MPO-ANCA titer does not correlate to disease.  A subset of MPO-ANCA 
patients have consistently high titers through active disease and remission, while other’s total 
autoantibody titers give no indication of a future relapse.  These inconsistencies underline the need to 
determine the epitope profile of individuals diagnosed with MPO-ANCA disease.  Efforts have been 
made to narrow MPO epitopes using over lapping peptides
20, 21
 and deletion mutants
24
 which are 
extremely limiting because of the assumption that anti-MPO autoantibodies will recognize linear 
epitopes.  In order to rectify the issues of conformation, human/mouse chimeric MPO molecules were 
produced; the limitations of these studies were based on the assumption that human anti-MPO would 
not cross react with mouse
22
.  In addition, chimeric molecules only presume to keep conformation 
static and do not enable fine epitope mapping because of the large segments of the protein assayed.  
In an attempt to remedy the limitations presented when using peptides and chimeras for epitope 
mapping, we utilized a proteomics technique which allows the use of uncompromised native human 
MPO purified from human leukocytes.  In the following investigation of anti-MPO ANCA epitopes a 
proteomics based approach referred to as epitope excision was adapted from Parker et. al.
51
   Our 
hypothesis is that epitope specific anti-MPO autoantibodies will correlate to disease activity more 
accurately than total anti-MPO titer.   
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Materials and Methods 
Patient Population and Diversity of MPO-ANCA disease 
In this study, 88 sera samples from 66 anti-MPO-positive patients with biopsy proven ANCA 
were collected for analysis.  The majority of the cohort were Caucasian (80.3%) and 54.5% were 
women.  The cohort consisted of 32/66 (48.5%) diagnosed with Microscopic polyangiitis (MPA), 
24.2% with renal limited disease, 21.2% with granulomatosis with polyangiitis (GPA), 4.5% 
eosinophilic granulomatosis with polyangiitis (E-GPA) and 1.5% with autoimmune disease overlap of 
SLE and MPO-ANCA vasculitis.  Also included were sera from 10 healthy volunteers for analysis by 
mass spectrometry with a mean age of 31.5 years (60% female, 70% Caucasian).  Healthy volunteers 
were screened for autoimmune diseases, hypertension and inflammatory diseases. Informed consent 
was obtained prior to all blood collections in accordance to UNC’s Institutional Review Board. 
Epitope Excision 
Total IgG was purified from sera using protein A/G PLUS-Agarose Reagent according to 
commercial protocol (Santa Cruz Biotechnology, Santa Cruz, CA).  Total IgG was bound to 0.2g 
CNBr-activated (1mM HCl) Sepharose 4B (GE Healthcare, Sweden) in compact reaction columns 
(CRC, USB Corporation, Cleveland, OH) for 2 hours at room temperature on an orbital rotator.  
Excess binding sites were blocked with Tris-HCl 0.1M pH 8.0 for 1 hour on an orbital rotator.  CRCs 
are then washed with alternating wash buffer (0.1M NaAcetate; 0.5M NaCl pH 4.0) and Tris-HCl 
0.1M pH 8.0 at least 10 times.  Columns are then equilibrated 5 times with PBS. Protein of interest, 
reconstituted in PBS, is bound to sepharose-IgG complexes (MPO, Elastin Products Co, Inc, 
Owensville, Missouri) for 3 hours on an orbital rotator.  Excess protein is removed by washing with 
PBS and the column is equilibrated with 50mM Nh4HCO3 pH 7.8 at least 10 times. At this time 
sepharose-IgG-MPO complex is then incubated with sequencing grade TPCK treated trypsin 
(Worthington, Lakewood, NJ) at 37°C on a shaker at 105rpm for 2 hours.  Excess protein digested by 
trypsin and no longer bound to antibody complex is removed by washing 10 times with PBS.  To 
elute remaining peptides bound by IgG, incubate with 0.1% trifluoroacetic acid (TFA) for 20 minutes 
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on an orbital rotator at RT.  Peptides are eluted twice in 150uL of o.1% TFA.  The sample is then 
desalted, concentrated and buffer exchanged into 50% ACN; 0.1% TFA using ZipTipc18 Pipette Tips 
(Millipore Corp., Billerica, MA).   
Determination of linear epitopes 
The same epitope excision method was used as stated above with the exception of protein 
binding.  Myeloperoxidase (80ug per sample) was predigested with 4:1 immobilized trypsin 
(Promega) overnight at 37°C.  Protein sample was centrifuged in a desktop centrifuge for 30 seconds 
and the supernatant containing the digested protein was used for protein binding. 
Heavy Oxygen labeling for low titer antibodies 
Heavy oxygen labeling was done on all remission samples (n=36) and healthy controls 
(n=10).  The above epitope excision protocol was followed until the trypsin digestion step.  The 
sample columns were washed with trypsin buffer made with H2
18
O (Cambridge Isotope Laboratories, 
Andover, Massachusetts) before digestion.  Trypsin was also reconstituted in H2
18
O and samples were 
digested for 2 hours at 37°C with agitation.  Proteins are labeled on the carboxy terminal with H2
18
O 
in a spontaneous reaction during the trypsin digestion of the protein.  After digestion, sample columns 
were washed 7 times with H2
18
O trypsin buffer.  Once H2
18
O isotope is introduced all buffers 
(including ziptip and elution) must be used with this isotope to prevent reversion to H2
16
O. 
Determination of DR2 Tg mice MPO epitope profile 
Total Ig was purified from sera from DR2 Tg mice immunized with either a control albumin 
peptide or a putative CD4+ T cell MPO epitope aa409-428 (PRWNGEKLYQEARKIVGAMV). The 
above epitope excision protocol in combination with MALDITOF TOF MS/M was utilized to 
discover antibody specificity.  The protocol was followed as outlined above with the exception of the 
protein of interest, recombinant mouse MPO protein was used as substrate (R&D systems). 
MALDI-TOF-TOF MS  
Samples were analyzed on a 4800Plus Matrix-Assisted Laser Desorption Ionization Time of 
Flight Mass Spectrometry (MADLI TOF/TOF MS/MS) in conjunction with ProteinPilot software 
(AB SCIEX, Foster City, CA).  The samples were spotted on a stainless-steel target with α-cyano-4-
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hydroxycinnamic acid matrix (Sigma).  The instrument has a YAG laser with λ=355nm and the 
potential difference between the source acceleration voltage and the collision cell was set at 2kV.  
Calibration was done internally with self digested TPCK treated trypsin.  Peak absorbances in MS 
spectra are not indicative of the abundance of peptide species because of the differences in individual 
peptides ability to ionize. 
All analysis was done with Protein Pilot using an NCBI Mascot search.  All MPO peptide 
samples were analyzed using the same search method: one missed cleavage, Homo sapiens origin, 
trypsin enzyme cut, 200ppm, 0.5 tolerance, +1 peptide charge, and variable modification of oxidation 
(M).  MPO epitope modeling was done using PyMOL Molecular Graphics System and MPO crystal 
structure PDB 3F9P. 
Enzyme-linked immunosorbent assay (ELISA) 
All peptides, peptide/beads and peptide columns were made at the UNC-Chapel Hill peptide 
synthesis center by Dr. David Klapper.  Costar ELISA plates (Corning, Inc., Corning, NY) were 
coated with approximately 1-2ug of peptide diluted in 100uL of bicarbonate binding buffer (pH 8.3) 
per well for 2h at RT.  Excess binding sites were blocked using SuperBlock PBS (Thermo Scientific, 
Rockford, IL).  Total IgG purified from sera using protein A/G PLUS-Agarose Reagent diluted 1:500 
were incubated overnight at 4°C.  Plates were washed 5x with PBST and incubated with goat anti-
human alkaline phosphate-conjugated secondary antibody (Millipore, Temecula, CA) for 1h on 
rocker. The plate was then washed 10x and 1-Step PNPP substrate (Thermo Scientific Rockford, IL) 
was applied for detected of antibody reactivity and read on a microplate reader after 30min at 
λ=405nm. 
Indirect immunofluorescence assay 
Indirect immunofluorescence (IFA) was assayed using INOVA Diagnostics, Inc. (San Diego, 
CA, 708290) with provided protocol.  One drop of positive and negative controls were incubated 
alongside 15ug patient IgG diluted 1:100 in PBS per slide in a moist dark chamber for 25-35 minutes. 
The wells were washed with 1x PBS in such a manner so as to eliminate cross contamination 5x.   
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Samples were then incubated with fluorescent conjugate for 25-35 minutes in a dark moist chamber. 
Repeat wash with 1x PBS, slides were mounted with a coverslip before being observed on an 
Olympus BX61 microscope (40x oil lens) using a Hamamatsu C10600 (ORCA-R2) Digital Camera.  
All indirect immunofluorescence slides were analyzed by J.C. Jennette. 
Neutrophil activation 
Human neutrophils from healthy donors were purified using 1 part HetaCep (Sigma-Aldrich) 
to 5 parts whole blood.  Samples were centrifuged for 6min at 100 x g at RT with break off.  Cell 
separation occurs after 15min at RT and plasma and lymphocyte layers are removed.  Cells were 
layered over 9mL of Histopaque (Sigma-Aldrich) and spun at 1200rpm for 15min and then 1100rpm 
for 15min at 4°C.  The pellet was resuspended in 10mL sterile 0.5x PBS (Cellgro) for 20sec, then 
immediately 3.3ml of 0.5x PBS was added and mixed well.  Cell were spun at 1100rpm for 9min and 
the subsequent pellet was resuspended in HBSS+/+ at a cell concentration of 1x10
7
.  For neutrophil 
activation, 1ul/mL of cytochalasin B was added to the isolated neutrophils and placed on ice for 
15min.  75uL of treated cells were used per well of a 96 well plate and incubated with: 20uL +/-SOD 
10uL ferricytochrome C, 10uL PMA, 10uL of affinity purified IgG and HBSS +/+.  Duplicate wells 
were used without SOD as controls.  Plate was kept at 37°C and read in a microplate reader at 37°C 
550nm every 10min for 60min. 
Statistical analysis  
P values were calculated by Wilcoxon two sample tests for two samples comparisons, 
Kruskal-Wallis Test for three groups comparisons and Signed Rank Test for paired groups 
comparisons. The Bonferroni correction, α=0.05/3 =0.167 should be used for multiple comparisons. 
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Results 
Identification of Natural Myeloperoxidase Specific Epitopes in Healthy Controls 
To test our hypothesis that epitope specificity of anti-MPO autoantibodies are linked with a 
pathogenic event, we first established a profile of antigenic determinants, or epitopes, of naturally 
occurring anti-MPO in healthy individuals using the epitope excision method illustrated in Figure 2.1.   
Figure 2.1 Epitope Excision with MS 
 
Figure 2.1 Epitope excision method for conformational epitope mapping of MPO. Immobilized antibodies 
purified from patient sera are bound to native MPO and the epitope is excised by digestion with trypsin (with or 
without the addition of 
18
OH2) to determine the specificity of autoantibodies to MPO while retaining 
conformation.   
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Because these ‘natural’ autoantibodies exist at very low titers, heavy oxygen (18OH2) labeling 
was incorporated into the protocol in order to increase sensitivity and specificity.  Heavy oxygen 
(
18
OH2) labeling is a technique used in proteomics, in place of radioactive isotope labeling, in order to 
have physical confirmation of amino acid presence identified by a known shift in mass number
52
.  
Natural autoantibodies found in healthy controls are at such a low titer that heavy oxygen labeling 
was essential.  To the best of our knowledge, this work represents the first report of application of the 
16
O-to-
18
O exchange technique to epitope mapping.  The details of the labeling reaction are shown in 
Figure 2.2. 
Figure 2.2 Labeling with heavy oxygen (
18
OH2) 
 
Figure 2.2 An approach with greater sensitivity was required for epitope excision for epitope mapping 
antibodies from healthy individuals. Using trypsin digestion as the catalyst to the reaction in the exclusive 
presence of 
18
OH2 isotope, the carboxy end of the cleaved protein adds 18O- and raises the mass unit of the 
cleaved peptide 4 mass units.  The shift in mass is used to identify the physical presence of the MPO peptide. 
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A total of seven epitopes were identified from control sera and were considered to be the 
targets of naturally occurring autoantibodies.   Epitopes were divided into two categories, 
conformational epitopes and linear epitopes, based on their structure and interaction with the 
autoantibody’s variable region.  A conformational epitope is composed of discontinuous sections of 
the antigen’s amino acid sequence or is dependent on tertiary structure or a particular 
microenvironment for antibody binding.  An epitope was determined to be linear if autoantibody 
binding was not disrupted by incubation with pre-digested protein. Seven epitopes were found in 
healthy subjects.   Most epitopes were determined to be conformational; four of seven epitopes 
identified were determined to be conformational and three of the seven were linear.   
Epitope profiling of anti-MPO antibodies from patients with MPO-ANCA glomerulonephritis 
After uncovering the epitopes targeted by naturally occurring autoantibodies we wanted to 
examine the epitope repertoire of patients with MPO-ANCA glomerulonephritis and if the same 
naturally occurring autoantibodies could be observed.  To determine the epitope profiles of patients 
diagnosed with MPO positive glomerulonephritis the same epitope excision with MS analysis (Fig. 
2.1) was used.  These methods were performed on 88 sera samples from 66 unique individuals.  Of 
the aforementioned sera samples 52 samples were from patients during active disease and 36 samples 
from patients in clinical remission.  The distribution and frequency of the total data collected is shown 
in Table 2.1.  Of the clinical remission sera samples, 26/36 were negative for MPO specific epitopes 
when using MS with heavy oxygen labeling.  Of the remaining 10 samples in which MPO-ANCA 
epitopes were detectable, the epitope specificity aligned with naturally occurring autoantibodies 
(Table 2.1).  The lack of MPO epitopes found in samples during disease remission is possibly a 
consequence of immunosuppressive therapies. 
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Table 2.1 MPO-ANCA epitope profiles 
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A summary of mass spectrometry epitope excision data is depicted graphically in Figure 2.3.  The 
epitope profiles from all 88 samples divided into two distinct categories: autoantibodies associated 
with disease or not associated with disease.  Disease associated autoantibodies and their 
corresponding epitopes were defined by appearance in samples taken during active disease only, per 
physician’s review of patient medical records.  Common epitopes (n=7) existed in both disease and 
controls groups and these were determined to be non-pathogenic. Naturally occurring autoantibodies 
were present in MPO-ANCA positive sera, in conjunction with an additional 18 unique disease-
restricted epitopes.  One hundred percent (52/52) of MPO-ANCA patients with active disease had at 
least one disease restricted epitope, i.e. not present in healthy individuals.   
Figure 2.3 MPO-ANCA epitope summary 
 
Figure 2.3 MPO epitopes found in patients and controls are distributed into categories of disease association.   
All 52 patients analyzed during active disease had autoantibodies specific to epitopes associated with active 
disease only and remission/ healthy subjects.   anti-MPO specific autoantibodies were found in healthy subjects 
and samples taken from ANCA patients during clinical remission in extremely low levels .  A more sensitive 
method was used by the addition of 
18
OH2 labeling to detect these epitopes.  This method was not needed to 
detect these same epitopes in MPO-ANCA patient samples during active disease.  
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Characterization of conformational and linear epitopes 
An epitope was confirmed as conformationally dependent if binding was disrupted by 
incubation with pre-digested protein and this characterization was confirmed by peptide ELISA.  
Peptides of three predicted conformational epitopes (aa490-499, aa461-473 and aa593-603) were 
confirmed to be structurally dependant when assayed against MPO-ANCA patient sera samples 
(n=40) (Fig. 2.4).   All sera samples did not react to the conformational epitopes tested. 
Figure 2.4 Conformation dependent epitopes do not react by peptide ELISA 
 
Figure 2.4 Three epitopes which were determined to be conformational were confirmed by peptide ELISA.  
MPO-ANCA active patient sera (n=40) were all unreactive to epitopes aa490-499, aa461-473 and aa593-603 by 
peptide ELISA which was predicted using epitope excision with pre-digested MPO. 
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Linear epitopes not associated with disease (n=3) were also verified for reactivity by peptide 
ELISA (Fig. 2.5).  Autoantibodies specific to linear epitopes (3/7) were indentified in sera from 10 
healthy subjects and two more linear epitopes were identified in MPO-ANCA patient samples.  
Reactivity was present in sera of healthy subjects, patients with active ANCA disease and disease 
remission when assayed against linear epitopes aa579-590, aa237-248, aa530-536; suggesting that 
these autoantibodies are not disease related.  These naturally occurring autoantibodies trend towards 
exhibiting higher reactivity in MPO-ANCA patient samples.   
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Figure 2.5 Linear MPO epitopes not associated with disease are reactive by peptide ELISA 
 
Figure 2.5 Sera from healthy controls (HC) and MPO-ANCA patients during active disease and clinical 
remission were assayed by ELISA to verify reactivity to linear epitopes not associated with disease.  Panel A-C 
epitopes: aa579-590, aa237-248, aa530-536 respectively which were found in healthy subjects using heavy 
oxygen labeling and confirmed by peptide ELISA.   
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Strictly disease associated MPO epitopes included two linear sequences aa516-524 
(YQPMEPNER) and aa448-459 (RKIVGAMVQIITY).  These were also confirmed for reactivity by 
peptide ELISA.   Approximately, 50% of MPO-ANCA patient samples tested were positive for an 
autoantibody specific for aa516-524 by both epitope excision and ELISA.  At first evaluation (Fig. 
2.6A ) the level of reactivity was similar in sera during active disease and remission.  However, 
analysis of paired samples from the same patients over the course of disease indicated this 
autoantibody was more prevalent during active disease (Fig. 2.6C).   
The second disease-associated linear epitope aa448-459 (RKIVGAMVQIITY), when tested 
by ELISA, gave conflicting results: reactive by MS and unreactive by ELISA.  A major difference 
between the two analyses was that whole sera was used for ELISAs but purified immunoglobulin (Ig) 
in MS.  When the ELISA was repeated substituting Ig for sera, the expected reactivity was observed 
(Fig2.6B).   Reactivity to MPO epitope aa448-459 was not observed in any disease remission samples 
tested by either assay.  Further, when reactivity is assayed in paired samples from the same 
individual, first at active disease and second during clinical remission, a more dramatic picture of 
disease association is identified (Fig. 2.6D).  This specific autoantibody targeting MPO epitope 
aa448-459 has potential to correlate with disease activity.  The discrepancy of the use of sera or Ig for 
reactivity to MPO epitope aa448-459 will be discussed in depth in Chapter 3.
44 
 
Figure 2.6 Disease associated linear epitopes are reactive by peptide ELISA 
 
Figure 2.6 Verification of seroreactivity to predicted linear disease associated MPO epitopes found by epitope 
excision.   Disease associated epitope aa516-524 (Panel A) shows specificity to ANCA disease but is also 
present during disease remission (Panel B).  A second linear disease associated epitope aa448-459 was found to 
be unreactive by ELISA using sera.  Total IgG was then used in place of serum to study reactivity to epitope 
aa448-459 by peptide ELISA which in Panel C and D shows a correlation to disease activity. 
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Anti-MPO aa448-459 autoantibody titers correlate with disease activity 
A subset of patients with MPO-ANCA have consistently positive (above 20) autoantibody 
titers by antigen specific ELISAs even during long term remission.  The following compilation of 
data shows that autoantibodies in the makeup of clinical titer include autoantibodies not associated 
with disease or natural autoantibodies.  Figure 2.7 shows that disease associated MPO epitope aa448-
459 has a more accurate link to disease activity than overall ANCA titer.  In this particular case study 
anti- aa448-459 autoantibody titer (shown in dotted line) rises immediately preceding a relapse and is 
more consistently negative during periods of remission (shaded areas)  compared to whole anti-MPO 
titer (solid line).   
 
Figure 2.7 Case study of MPO-ANCA patient with consistently high titer anti-MPO 
 
Figure 2.7 A case study of an individual with MPO-ANCA shows a consistently positive anti-MPO titer (above 
20) from February 2005 to May of 2011.  Relapses are marked by arrows contrasting shades of gray which 
represent possible times of disease remission.  The dotted line shows the titer of disease associated autoantibody 
anti-aa448-459 which more closely follows disease activity in this particular patient over the course of disease.  
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To further study this population, seven patients whose autoantibody titers are consistently 
between 40-100 (regardless of disease activity) were assayed for reactivity to MPO epitope aa448-
459.  The results shown in Figure 2.8 reveal an association with disease activity much more readily 
than whole anti-MPO titer.  Importantly, during disease remission the whole ANCA titer, which is 
high in this cohort of patients, is made up of epitopes not associated with disease.   It is important to 
note that there may be disease associated conformational epitopes that also correlate with disease 
activity that cannot be studied by ELISA.   
 
Figure 2.8 Anti-aa448-459 titer correlates with disease activity 
 
Figure 2.8 Disease associated autoantibody anti-aa448-459 consistently correlates with disease activity.  Seven 
MPO-ANCA patients whose total anti-MPO titer does not decrease to normal levels during remission were 
assayed for the specific anti-aa448-459 antibody.  Anti-448-459 antibody levels (solid line) decrease during 
remission in every case. 
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Epitope profiles are consistent within individuals upon relapse of disease 
MPO-positive GPA patients relapse infrequently but when a relapse occurs it is important to 
examine if the same B cell clones are returning to produce similar autoantibodies or does a new set of 
clones emerge which  target different MPO epitopes.  Within our cohort of MPO-positive patients, 
there were five patients who had multiple active samples taken over the course of their disease; 
consisting of either onset of disease/relapse or relapse/remission/relapse. Epitope profiles were 
analyzed to determine changes in B cell clonal restriction (Table 2.2).  The data indicate that the 
antibody specificity of a patient remains constant throughout the course of their disease.    
 
Table 2.2 The same B cell clones return during disease relapse 
Patient Number 
Number of Epitopes 
at Disease 
Onset/Relapse 
Number of Epitopes 
at Relapse 
Proportion of 
homologous epitopes 
that return 
1 3 15 3/3 
2 13 5 5/5 
3 13 15 10/13 
4 15 13 13/15 
5 14 8 8/8 
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Disease associated MPO specific epitopes have pathogenic potential. 
It is well known that ANCA target MPO on the surface of neutrophils in vivo and cause them 
to degranulate and damage endothelium resulting in small vessel vasculitis.  We can replicate this 
phenomenon in an in vitro assay using cytoclasin B primed neutrophils from healthy donors.  Affinity 
purified autoantibodies were tested for their ability to activate neutrophils using an established 
neutrophil activation assay
4
.  Autoantibodies that targeted linear epitopes were affinity purified and 
specificity was confirmed by ELISA (Fig. 2.9).  First, specificity was determined by assaying a 
specific autoantibody against varying epitopes and second, reactivity and purity were assayed against 
each MPO peptide using all affinity purified autoantibodies. Characterization of eluted antibodies 
verified that the aa448-459 affinity purified autoantibodies reacted specifically aa448-459 peptide by 
ELISA and was negative for five non-specific peptides (Fig. 2.9A and C).  Specificity was further 
validated when other anti-MPO antibodies purified by chromatography did not react with peptide 
aa448-459 (Fig. 2.9B and D).   Once specificity and purity were examined by ELISA affinity purified 
autoantibodies were utilized for indirect immunofluorescence on fixed neutrophils and assayed for 
their ability to activate neutrophils from healthy donors.   
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Figure 2.9 Reactivity and specificity of affinity purified anti-MPO by ELISA 
 
Figure 2.9 Peptide ELISAs utilizing affinity purified epitope specific autoantibodies from patient sample were 
assayed for reactivity and specificity to their corresponding peptides.   Reactivity and purity was assayed 
against peptide aa530-536 (Panel B) and aa448-459 (Panel D) coated plates and reactivity of their 
corresponding antibodies in addition to other affinity purified autoantibodies.   Specificity was determined by 
the reactivity of the affinity purified antibodies to a variety of MPO peptide substrates including native MPO as 
a positive control (Panel A and C).  
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 Figure 2.10 shows the result of neutrophil activation by release of oxygen radicals utilizing 
neutrophils from four healthy donors.  Total anti-MPO, anti-aa448-459, anti-aa516-524 and 
autoantibodies specific for conformational epitopes all activated healthy neutrophils (Fig. 2.10A).  
Autoantibodies found in healthy controls and during remission (not associated with disease) did not 
cause neutrophil degranulation (Fig. 2.10B).  These results correlate to the individual autoantibody’s 
prediction of disease association from the MS epitope excision. 
Figure 2.10 in vitro pathogenic potential of affinity purified anti-MPO 
 
Figure 2.10 Comparison of MPO specific autoantibodies with and without association with disease by 
pathogenic potential.  Neutrophil activation assays were done on neutrophils from 4 healthy individuals.  Panel 
A displays the ability of disease associated autoantibodies to activate primed healthy neutrophils.  In contrast, 
Panel B shows the result of neutrophil activation assays using autoantibodies from healthy individuals and 
patients which are not associated with disease.    
51 
 
Affinity purified antibodies were assayed for staining patterns on fixed human neutrophils by 
indirect immunofluorescence using the INOVA-ANCA IFA used by UNC hospitals for clinical 
diagnostic testing.  Figure 2.10 shows the resulting staining patterns A) anti-MPO from a healthy 
individual B) total anti-MPO from an MPO positive patient C) affinity purified anti-aa530-536 D) 
anti-aa579-590 E) anti-aa516-524 F) anti-conformational epitope antibody pool.  MPO positive stain 
exhibits a peri-nuclear pattern which can be seen on Fig 2.11B, E and F; while A, C and D are 
negative.   Negative stains resulted from anti-MPO autoantibodies purified from healthy subjects (A) 
and autoantibodies purified from patients that target epitopes not associated with disease (C and D).  
Disease associated epitope aa448-459 does not stain healthy neutrophils and will be discussed further 
in Chapter 3. 
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Figure 2.11 Indirect immunofluorescence assay of affinity purified anti-MPO on human neutrophils 
 
 
Figure 2.11 Reactivity of affinity purified autoantibodies to fixed human neutrophils using the INOVA-IFA 
clinical assay.  Panel A shows affinity purified anti-MPO from a healthy individual in contrast to anti-MPO 
from a patient sera sample (Panel B).  Panel C and D show a negative stain from autoantibodies not associated 
with disease anti-aa530-536 and anti-aa579-590 respectively.  A perinuclear pattern is shown in Panel E by 
reactivity with linear disease associated epitope anti-aa516-524.  An even more intense staining pattern is seen 
in Panel F by staining with a pool of autoantibodies to all conformational MPO specific epitopes. 
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Verification of reactivity to linear MPO epitopes in an independent patient cohort 
The independent cohort from Groningen, The Netherlands consisted of 26 active samples 
with 26 longitudinal remission samples from 26 patients with MPO-ANCA, nine healthy controls and 
five Ig samples from patients with PR3-ANCA.  Epitope profiles were determined from 20 active Ig 
patient samples included in the previously described cohort (Table 2.3). 
Table 2.3 The Netherlands patient cohort; MPO epitope profiles 
 
 
The most prevalent disease associated epitope aa537-548 in our US cohort was also the most 
prevalent in the NL cohort but the distribution was not similar.  The epitopes displayed in Table 2.3 
are ordered by prevalence in the US cohort and do not correlate with the prevalence in the NL cohort 
indicated by the totals at the bottom of the table.  There are also six epitopes that are not represented 
in the NL patient cohort.  In addition to epitope profiling, disease associated anti-MPO
448-459 
and anti-
MPO
516-524 
autoantibodies were assayed for reactivity and specificity by ELISA.  The results, which 
are consistent with the MS data, are shown in Figure 2.12. 
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Figure 2.12 Reactivity to critical epitopes in an NL cohort by ELISA 
 
Figure 2.12  Purified Ig was assayed against two disease associated epitopes aa448-459 and aa516-524. Panel 
A shows the overall reactivity to MPO epitope aa4484-459 and Panel B shows the 12 samples positive for 
epitope aa448-459 by MS assayed by ELISA with longitudinal samples from the same individual.  Panels C and 
D show the reactivity of Ig against MPO epitope aa516-524 using the NL cohort and longitudinal samples from 
the same individual positive for the epitope by MS respectively.
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In vivo immunization of a CD4+ T cell epitope induces glomerulonephritis in DR2 Tg mice 
ANCA are implicated in the pathogenesis of vasculitis and FNGN 
5, 13, 53
, but although there 
is a rationale for autoreactive CD4
+
 cells, there is less evidence of a role for cell-mediated effectors.   
We hypothesize that MPO-specific effector CD4
+
 cells are important in disease by localizing to 
glomeruli and inducing a DTH-like lesion. The existence of autoantigen specific T cells, together 
with the presence of effector CD4
+
 cells, macrophages and fibrin in patients’ glomeruli provide the 
foundation for our hypothesis. MPO within the glomerulus exists both within neutrophils and 
extracellularly 
54
.  In a murine model of anti-MPO FNGN, where autoimmunity to MPO is induced 
and glomerulonephritis is triggered by injection of sheep anti-mouse glomerular basement membrane 
(GBM) antibody, CD4
+
 T cell depletion during the effector phase attenuated disease 
55
. 
To study the potential immunopathogenecity of MPO epitope aa448-459 in vivo, our 
colleagues at the Monash Medical Center in Victoria Australia were able to immunize mice (human 
DR2) with an overlapping T cell epitope.  We were provided sera from their MPO mouse model. 
They have used this epitope to test the hypothesis that antigen specific CD4
+
 T cells recognize this 
epitope and MPO itself, in glomeruli and induce FNGN.  In addition to CD4
+
 T cells recognition of 
the MPO epitope, we tested if the sera to determine the MPO epitope profile produced when mice 
were immunized with just one epitope. The immunodominant CD4+ T cell epitope was identified in 
mice immunized with 20 amino acid overlapping peptides spanning the murine MPO molecule.   
Immunization with MPO aa409-428 (PRWNGEKLYQEARKIVGAMV) in combination with 
Fruend’s complete adjuvant was confirmed to induce glomerulonephritis by injection at the base of 
the tail of DR2 Tg mice. This T cell epitope overlaps with our disease associated B ell epitope aa448-
459 (RKIVGAMVQIITY).   DR2 Tg mice have a human DR2 and immunization caused nephritic 
autoimmunity and an autoantibody B cell response.  Mass spectrometry analysis using the previously 
described method was performed on the immunoglobulin fraction from sera of four MPO aa409-428 
immunized DR2 Tg mice against murine MPO.  The epitope profile of the humanized mice is 
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compared with human epitopes found using the same method in Table 2.3.  The majority of the 
antibodies target MPO epitopes in regions of homology between murine and human MPO.  As seen 
in Table 2.3, the epitope profiles from the DR2 Tg mice not only developed antibodies targeting the 
initial peptide immunogen but also initiated a polyclonocal response to the entire MPO molecule 
which targeted similar epitopes as an MPO-ANCA patient profile.  
When this in vivo data is considered in addition with published data on the pathological role 
of ANCA in disease, our studies demonstrate that tissue injury in microscopic polyangiitis is 
mediated by a series of events. These events include distinct roles for both MPO-ANCA activated 
neutrophils, autoreactive effector CD4
+
 T cells that provide further evidence to support the 
immunopathogenecity of not only ANCA but a specific anti-aa448-459 autoantibody. 
 
 
 
Table 2.4 Comparison of human and murine MPO epitope profiles 
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Discussion 
In this chapter, anti-MPO epitope specificity was identified using an epitope excision 
proteomics approach with patient and healthy donor sera samples.  A total of 25 MPO epitopes were 
found including: 12 associated with active ANCA disease, six associated with ANCA disease 
(including remission), and seven not associated with disease.  By pre-digestion of MPO, 5/25 
epitopes were determined to be linear, with the remaining 20 epitopes which were conformationally 
dependant.  This finding is consistent with two initial reports identifying that MPO-ANCA recognize 
mostly conformational epitopes
19
 and patients have a polyclonocal response
56
.   
Immunodominant MPO epitopes have been identified in patient cohorts around the world 
with little to no consensus.  The initial report of anti-MPO specific epitopes by Pedrollo et. al. 
incriminate the denatured light chain of a bacterially expressed recombinant MPO protein.  All 
patients tested (n=20) were reactive to whole native protein, 11 were reactive to the urea denatured 
light chain and zero were reactive to the denatured heavy chain.  They concluded that most epitopes 
were conformationally dependent while the light chain held linear epitopes that were readily 
recognized by MPO-ANCA sera samples
57
.  We have been able to confirm these initial results 
showing that there is a linear epitope found in the light chain (aa237-248) along with 3 other 
conformational epitopes.   
In 1995, Chang et. al. studied the reactivity of five MPO-ANCA patients sera samples against 
overlapping peptides spanning the entire MPO molecule.  They found four epitopes that were 
significantly reactive to patient Ig but Ig from healthy controls were reactive to the same four 
epitopes
21
.  The epitopes that were reported in this study have overlap with our identified epitopes 
associated with disease only.  These epitopes are not linear and would not be accessible using 
overlapping peptides.  Chang and colleagues concluded that the reactivity seen in their assays was 
nonspecific. 
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A group in Japan published a series of manuscripts studying immunodominant MPO epitopes 
using recombinant MPO fragments
24, 58, 59
.  There has been no characterization of the structure of the 
recombinant fragments or whether they are similar to native MPO.  The initial report in 1998 presents 
a single region where reactivity was seen in all five patients tested.  This large region of the heavy 
chain, which includes 141 amino acids, overlaps with three disease associated conformational 
epitopes we have found by epitope excision.  In 2000, the same recombinant fragments were used to 
assay 20 MPO-ANCA patient sera samples.  Using a larger cohort produced two narrower regions of 
reactivity (aa279-341 and 341-410) which were within the range of the initial finding and one 
additional region of 148 amino acids at aa598-745.  It should be noted that the narrowing of the initial 
range did not exclude any epitopes we have found in that same region.  The additional range overlaps 
with two epitopes not associated with disease and three disease associated epitopes which were all 
found to be conformationally dependent for antibody interaction.  Their most recent paper published 
in 2007, again used their recombinant MPO fragments on an even larger population of MPO-ANCA 
patients (n=74) in order to study the link with disease severity.  They were able to further narrow their 
epitope ranges to two sequences (aa279-341 and aa474-512) which in our studies overlaps to three 
disease associated epitopes which are conformationally dependent. 
In an effort to rectify the gathering evidence of conformational dependent MPO epitopes and 
to preserve molecular architecture, Erdbrugger et. al. constructed human/mouse chimeras
22
.  Their 
advantage was the close homology (90%) between murine and human MPO which in theory would 
equate to a similar structure to native MPO.  The MPO molecule was divided into five segments:  
light chain, and 4 segments of the heavy chain (A-D).  They found the most reactivity (n=14 patients 
with n=43 samples) in segments C (aa517-667) and D (aa668-745) which in combination is a total of 
249 amino acids.  The results presented in this chapter confirm that 12 epitopes fall within these two 
segments.  Erdbrugger et. al. also found that 6/14 patients in at least one sample reacted with their 
segment B (aa387-516) which overlaps with an additional seven epitopes found by epitope excision.  
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While using chimeras yielded many more results than overlapping peptides, the regions of reactivity 
were too large to predict any specific immunodominant epitopes. 
The most recent report is from Bruner et. al. in 2011, where they implicate seven 
immunodominant epitopes by utilizing an overlapping peptide ELISA
20
.  We were able to confirm 
one of their immunodominant epitopes aa511-522 (RLDNRYQPMEPN) which overlapped with our 
linear disease associated epitope aa516-524 (YQPMEPNPR).  Five other epitopes which we 
identified by MS epitope excision also overlapped with their linear epitopes but we determined that 
they were conformational.  In this recent study, their cohort was limited to 14 individuals with MPO-
ANCA which could have lead to the discrepancy in results. 
Reviewing the literature describing potential MPO epitopes there is little evidence that points 
to a consistent ideally sized (3-5 amino acids) immunodominant epitope.  While there is consensus a 
that the anti-MPO autoantibody response is polyclonal, the heavy chain holds the majority of disease 
associated epitopes and the majority of epitopes recognized by human anti-MPO autoantibodies are 
conformational.  The idea of an immunodominant MPO epitope may only be relevant on an 
individual patient basis.  Table 2.4 summarizes these findings and illustrates the overlap with the 25 
epitopes presented determined by MS.   
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Table 2.5 Comparison of reported MPO epitopes 
Manuscript 
(Author, year) 
Protein substrate 
Patient 
cohort 
Epitope
#
 Overlap 
My pathogenic 
prediction* 
Pedrollo E., 1993 
Bacterially 
expressed 
recombinant 
n=20 
Denatured Light 
chain 
aa166-278 
aa184-193 DA 
aa198-219 DA 
aa220-228 DA 
aa237-248 NDA 
Chang L., 1995 
Overlapping 
peptides 
n=5 
aa119-130 
aa179-180 
aa439-450 
aa649-670 
aa442-447 DA 
aa437-441 DA 
aa657-664 DA 
Tomizawa K., 1998 
Recombinant 
protein fragments 
n=4 aa269-409 
aa328-351 DA 
aa369-405 DA 
aa396-405 DA 
Fujii A., 2000 
Recombinant 
protein fragments 
n=20 
aa279-341 
aa341-410 
aa598-745 
aa328-351 DA 
aa369-374 DA 
aa396-405 DA 
aa593-603 NDA 
aa605-622 DA 
aa678-691 NDA 
aa692-701 DA 
aa715-725 DA 
Erdbrugger U., 2005 
Human/mouse 
chimeric 
recombinant 
n=14 
aa517-667 
aa668-745 
aa516-524 DA 
aa530-536 NDA 
aa537-548 DA 
aa560-571 DA 
aa572-578 NDA 
aa579-590 NDA 
aa593-603 NDA 
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aa605-622 DA 
aa657-664 DA 
aa678-691 NDA 
aa692-701 DA 
aa715-725 DA 
Suzuki K., 2007 
Recombinant 
protein fragments 
n=74 
aa279-341 
aa474-512 
aa328-351 DA 
aa474-480 DA 
aa490-499 DA 
Bruner B.F., 2011 
Overlapping 
peptides 
N=12 
aa91-100 
aa213-222 
aa393-402 
aa437-446 
aa479-488 
aa511-522 
aa717-726 
Aa220-228 DA 
Aa396-405 DA 
Aa442-447 DA 
Aa474-480 DA 
Aa516-524 DA 
Aa715-725 DA 
# amino acid sequence based off of MPO sequence gi 34719 
*DA = disease associated epitope 
NDA = not disease associated 
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The search for an immunodominant epitope has obvious implications for the pathogenesis of 
disease but the development of these autoantibodies is another area of interest.  Natural 
autoantibodies (NAA) which are defined as antigen (MPO and PR3) specific autoantibodies found in 
circulation in blood samples from healthy donors were first identified and isolated in an effort to 
understand the mechanism of ANCA production
28
.  Purification of natural autoantibodies was done in 
2010 by Cui et. al. from IgG fractions from healthy donors (n=20)
28
.  Autoantigen specificity was 
proven by an indirect immunofluorescence assay (IFA) where both anti-PR3 and anti-MPO NAA 
showed a cytoplasmic pattern consistent with a positive PR3-ANCA IFA.  This is not consistent with 
our results where autoantibodies not associated with disease do not stain human neutrophils by IFA.  
This discrepancy could be due to the fact that we were only able to test the 3 NAA that were specific 
to linear epitopes.  Interestingly, Cui et. al. could not be detect NAA in serum or IgG fractions which 
is indicative of low titer antibodies, this finding correlates with our observations.   
In 2011 Xu et. al. compared the characteristics of NAA found in healthy individuals to 
patients with ANCA disease.  Plasma samples from five healthy blood donors and 10 patients with 
MPA were used to purify autoantibodies to MPO.  Autoantibodies were assayed for reactivity by 
ELISA, western blot, for titer, avidity, IgG subclass, neutrophil activation and MPO/CP binding.  
They found that anti-MPO NAA were lower titer, lower avidity, had a lower inhibitory effect on 
MPO/CP binding, a lower ability to activate primed neutrophils and were comprised of different IgG 
subclasses than MPO-ANCA from patients.  This report gives a full picture of the characteristics of 
the NAA which is in agreement with our results using epitope excision.  In order to further the 
knowledge of NAA in ANCA disease, we have identified the sequence of 7 epitopes on MPO that are 
the targets of NAA; 3 of which are linear.  Both reports admit that the role of NAA are still unclear 
but suggest that their role could be either protective or potentially pathogenic. 
We hypothesize that the presence of  NAA, autoantigens and autoantibody specificity are just 
some factors in a cascade of pathogenesis (likely variable between individuals) which results in 
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autoimmune disease
60
. Once we had determined epitope profiles from patient and healthy donor 
samples, the crystal structure of human MPO (pdb 3F9) was used to determine relationships between 
disease associated epitopes and non-disease associated epitopes. Disease associated epitopes shown in 
blue (Fig. 2.13) are in many cases found in conjunction with epitopes found in healthy individuals 
(green). Fine epitope mapping (shown in red) incriminates specific amino acids which are important 
for autoantibody binding in these pairs. We propose that individuals who express non-pathogenic 
MPO autoantibodies
28
 are likely to not develop disease; however, these same potentially non-
pathogenic autoantibodies in an individual with dysfunctional T cells
61-63
 could aberrantly display 
sequential variations of the epitope. These autoreactive T cells are able to stimulate B cells to produce 
autoantibodies that are now potentially pathogenic and create active disease associated autoantibodies 
targeted at previously unrecognized neighboring MPO sequences.  
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Figure 2.13 Hypothesis: Origins of disease associated epitopes 
 
Figure 2.13  Development of active disease associated anti-MPO autoantibodies through aberrant T cell antigen 
presentation.   In healthy individuals T cells present peptides to B cells that produce antibodies (left side) to 
MPO specific epitopes unrelated to autoimmune disease.   Disease associated and non disease associated 
epitopes were found in pairs and upon fine epitope mapping, critical amino acids (highlighted in red) that 
correlate with disease activity.   
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We postulate that epitope specificity of anti-MPO-ANCA may also depend greatly on the 
genetic background of the individual. MHC classes and HLA subclasses direct the immune response 
and illicit a wide variety of a clonal B cell response. There is a range of autoantibody production in 
individuals’ which may be dependent on their HLA subclass. The 52 active MPO-ANCA serum 
samples studied showed a wide range of B cell clonality. When patients were in an active disease 
state the range of unique autoantibodies found in their sera corresponding to 3-20 epitopes.  Also, 
within the same individual upon a disease relapse, the same profile of anti-MPO autoantibodies 
reemerge and tended to target the same MPO epitopes as previous active disease states. 
The amalgamation of the patient and animal data indicate that a MPO epitope aa448-459 
restricted response is sufficient to cause pauci-immune vasculitis, underscored by the restricted 
response found in ANCA-negative glomerulonephritis patients.  The murine MPO409-428 CD4+ T cell 
epitope can also induce MPO-ANCA in DR2 Tg mice.  While it is not necessary for autoreactive T 
and B cell epitopes to be from similar parts of the autoantigen, the identification of overlapping T and 
B cell epitopes in a similar region of the heavy chain of MPO with substantial cross reactivity 
strengthens the case for the relevance of this region of the MPO molecule in MPO-ANCA associated 
vasculitis. Targeted antigen-specific therapy is a long term aim in treating autoimmune disease. The 
identification of an important epitope within MPO provides a platform for further work aimed at 
developing antigen specific therapies, given the apparently relatively restricted range of autoantigens 
in microscopic polyangiitis with MPO-ANCA. 
When considered with the published data on the pathological role of ANCA in disease, our 
studies demonstrate that tissue injury in microscopic polyangiitis is mediated by a series of events. 
These events include distinct roles for both MPO-ANCA activated neutrophils, as well as 
autoreactive effector CD4
+
 T cells that recognize MPO planted in glomeruli by ANCA-activated 
neutrophils. 
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MPO-ANCA titers have not proven to be good markers of disease activity and their targets 
have been elusive until now
35, 64
.   Our data shows that the majority (18/20) of disease associated anti-
MPO-autoantibodies depend on a conformational structure for successful binding. Our current 
methods of testing autoantibody titers as a predictor of disease activity may be insufficient. The 
technique used in this study is drastically more sensitive than current clinical testing and has 
uncovered extremely low titer anti-MPO NAA found in healthy subjects as well as specific 
autoantibodies that correlate with disease activity. 
 
  
Chapter 3 
MYELOPEROXIDASE SPECIFIC AUTOANTIBODY IN ANCA-
NEGATIVE GLOMERULONEPHRITIS 
 
ANCA negative glomerulonephritis 
ANCA glomerulonephritis is the most common form of aggressive glomerular disease and is 
associated with a systemic necrotizing vasculitis including microscopic polyangiitis (MPA) and 
granulomatosis with polyangiitis (GPA).
14
  In general, patients with systemic necrotizing vasculitis 
have autoantibodies reactive with myeloperoxidase (MPO-ANCA), or proteinase 3 (PR3-ANCA).  
However, in some cases, patients with systemic necrotizing vasculitis have an ANCA negative 
serology.   In 2009, Chen et. al. retrospectively reviewed clinical data collected from patient charts of 
ANCA glomerulonephritis cases in China and the UK and determined that 10-30% of studied cases 
were ANCA-negative
62
.  The percentage of ANCA negative glomerulonephritis case varies widely 
and diagnosis is problematic with conflicting and inconsistent results from clinical testing.  For 
example, antigen specific ELISAs are negative while indirect immunofluorescence assays against 
human neutrophils show a positive staining pattern, or when a patient presents as ANCA negative but 
as their disease progresses clinical tests indicate a positive ANCA serology.  The observance of these 
clinical discrepancies, when taken as a whole, lead to the following possible hypothesis: 1) ANCA-
negative glomerulonephritis is a distinct syndrome; 2) autoantibodies are targeting an autoantigen not 
included in the clinical test; 3) existing clinical tests lack sensitivity and/or specificity. 
One of the MPO epitopes we have found to be exclusively prevalent in patients with active 
disease appears to be a critical immunodominant epitope found not only in ANCA positive patients, 
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but also is the sole reactive epitope in some patients with ANCA negative disease.  The reason for the 
inability to detect this anti-MPO antibody in conventional clinical tests is a consequence of its 
blockade by a fragment of the natural inhibitor of MPO, which is ceruloplasmin.  It is the discovery 
of an immunodominant epitope and corresponding anti-MPO autoantibody in ANCA negative 
patients hidden from conventional clinical assays that raises the possibility of similar phenomenon in 
other “seronegative” autoimmune diseases thereby opening a window into the possible 
experimental approach to exploring other autoimmune disease.  
In this chapter, we present experiments that revealed the existence of MPO-ANCA in sera of 
patients previously diagnosed as “ANCA negative systemic necrotizing vasculitis.”  We were able to 
discern a pathogenic epitope on MPO (aa448-459), which was previously identified as a linear 
epitope associated with disease (Chapter 2).  Autoantibodies to MPO epitope aa4484-59 were 
previously undetected in clinical assays due to a ‘blocking’ factor resident in serum.  Indications are 
that monitoring for this specific ANCA-epitope is a better indicator of not only MPO-ANCA disease 
activity but also it is important in the diagnosis of ANCA disease.   
Autoantigen epitope profiling in ANCA negative glomerulonephritis 
Eight patients diagnosed with ANCA negative glomerulonephritis were selected based upon 
clinical presentation with small vessel vasculitis with a negative result by indirect 
immunofluorescence microscopy or antigen-specific enzyme-linked immunosorbent assays (ELISA). 
Participants were included if they were persistently ANCA negative but had histological confirmation 
of the disease by a biopsy of the kidney, lung or upper respiratory tract consistent with pauci-immune 
small vessel vasculitis or glomerulonephritis, with or without granulomatous inflammation. Three 
patients with persistently negative ELISAs but positive p-ANCA by immunofluorescence were also 
included. The above patient population was 87.5% female and 62.5% Caucasian with a mean age of 
35.6 years.   
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Sera samples from patients diagnosed with ANCA negative glomerulonephritis (n=8) were 
assayed for autoantibodies by mass spectrometry using the MS epitope excision protocol (Chapter 2) 
with the exception that the total leukocyte cell lysate from a healthy donor was used as a non-biased 
substrate to search for unknown antigens.  All patients with ANCA-negative glomerulonephritis 
displayed a restricted autoantibody response to myeloperoxidase, specifically, to epitope aa448-459 
(RKIVGAMVQIITY).  Mass Spectrometry spectral analysis identifies the peptide bound to patient Ig 
is from myeloperoxidase.  In Figure 3.1 an MS spectrum from one ANCA-negative 
glomerulonephritis patient shows the peptide at a mass of 1491.841.   
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Figure 3.1 Autoantibody specificity in ANCA-negative glomerulonephritis by MS 
 
Figure 3.1 Immunoglobulin fractions were purified from patient sera and subjected to epitope excision and MS 
analysis (Panel A).  Patients were found to have a restricted autoantibody response to MPO.  MS analysis 
revealed autoantibody binding to an MPO fragment mass of 1492.14, identifying the epitope as aa448-
459(Panel B).
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Upon further analysis MPO epitope profiles were determined for all twelve patient samples.  
Table 3.1 shows the epitope profiles of the 8 patients studied in this cohort (four of which had 
samples also during disease remission), all active samples identified only one disease associated 
epitope, MPO epitope aa448-459. 
 
 
 
Reactivity was confirmed by ELISA using the native MPO and MPO peptide aa448-459 as 
substrate (Fig. 3.2).  The results of the ELISA show that in comparison to healthy subjects, the Ig 
fraction is reactive against native MPO (Fig. 3.2A) and epitope aa448-459(Fig. 3.2B).   Paired 
samples from four of the eight patients were also assayed for reactivity by both substrates by ELISA 
(Figure 3.2C and D).  Samples were collected during active disease exhibited reactivity to native 
MPO, while samples collected during disease remission had significantly decreased reactivity.  The 
data correlate with the initial observation of anti-aa448-459 autoantibodies in active MPO-ANCA 
disease.   
Table 3.1 MPO epitope profiles from patients diagnosed with ANCA-negative glomerulonephritis 
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Figure 3.2 Reactivity of anti-aa448-459 in ANCA-negative glomerulonephritis 
 
Figure 3.2 Reactivity to MPO epitope aa448-459 and native MPO were assayed by ELISA with samples from 
ANCA-negative glomerulonephritis patients (n=8) and healthy individuals (n=15, n=20).  Panels A and B show 
the seroreactivity of Ig from ANCA-negative sera against native MPO and the synthetic peptide aa448-459, as 
compared to healthy controls.  Panels C and D display the correlation of anti-MPO reactivity with disease 
activity using paired samples from the same individual during active disease and clinical remission. 
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It is important to note that all assays were carried out using the Ig fraction purified from 
patient sera whereas both ELISA and IF clinical assays used whole sera.  We hypothesized that the 
failure of detecting anti-aa448-459 autoantibodies in the clinical assay was due to masking by a serum 
component.  To test this hypothesis, ELISAs were used to test the reactivity against native MPO and 
MPO peptide aa448-459 using both sera and Ig fraction from the same sample.  Figure 3.3 shows that 
a positive autoantibody reactivity against native MPO or MPO peptide aa448-459 by ELISA was 
highly dependent on using purified Ig, while results were negative using the same patient’s whole 
serum (Fig. 3.3A and B).  These results are consistent with the prediction of a serum ‘epitope-
blocking’ factor observed in Chapter 2.  Further, this observation was confirmed by an inhibition 
experiment in which increasing amounts of serum were added to reactive Ig fractions and all 
reactivity was blocked (Fig 3.3C).  The addition of sera from a healthy individual or a MPO-ANCA 
patient yielded a steep reduction of reactivity at a concentration of 1:1000 (Ig : sera).   It was 
determined that the serum component is abundant in sera and is not disease specific. 
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Figure 3.3 Seroreactivty to MPO using sera and Ig 
 
Figure 3.3 Sera from eight ANCA-negative glomerulonephritis patients were assayed against native 
MPO(Panel A) and a synthetic peptide of epitope aa448-459 (Panel B).  All sera were non-reactive in contrast 
to total Ig.  Titration of serum, from both a healthy subject (dashed line) and a patient serum (solid line), into 
total Ig preparations blocked reactivity to MPO peptide aa448-459 (Panel C). 
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Ceruloplasmin blocks anti-448-459 autoantibody interactions on native MPO 
To identify the ‘blocking-factor’ present in sera, MPO peptide aa448-459 (irreversibly bound 
to polystyrene beads) was used to discover potential binding partners.  Peptide beads were incubated 
with sera from patients and healthy individuals.  The stained gel of eluted proteins showed a band on 
all five healthy control and five active MPO-ANCA patients at ~151kD (Fig. 3.4A).  There was also a 
protein band of approximately 50kD in size.   Both bands were excised for sequencing by MALDI-
MS/MS and were identified as ceruloplasmin (CP).  MALDI-MS/MS data was confirmed by western 
blot using a ceruloplasmin specific polyclonal antibody (Fig. 3.4B).   A western blot probed with a 
polyclonocal anti-CP antibody recognized both sizes of protein one at 151kD (full length CP) and 
about 50kD (CP fragment).  From this data we were able to determine that full length CP and a 
smaller CP fragment are both able to bind specifically to MPO epitope aa448-459.  There are no 
obvious differences in amount of CP that bound to MPO peptide aa448-459 between healthy subjects 
and active MPO-ANCA patients by western blot. 
73 
 
 
Figure 3.4 Identification of serum component bound to aa448-459 
 
Fig 3.4  Sera ‘epitope-blocking’ factor was purified using the target MPO epitope aa448-459 and analyzed by 
gel electrophoresis.  Distinct bands at ~150kD can be detected in all 10 samples irrelevant of disease (A).  The 
gel was transferred to nitrocellulose and probed with an anti-ceruloplasmin polyclonal antibody which 
confirmed that bands at ~150kD and ~50kD were full length ceruloplasmin and a protein fragment, respectively 
(B). 
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To study the inhibition of ANCA binding to the MPO epitope aa448-459 in vitro, full length 
CP and also the smaller CP fragment were required.  In order to replicate the CP fragment at ~50kD, 
full length CP was digested by a variety of serum proteases shown in Figure 3.5.  Serine proteases 
chymotrypsin, plasmin, thrombin and urokinase were determined to digest CP into appropriate sized 
fragments whereas lysozyme digestion did not. Plasmin, thrombin and urokinase were chosen as 
candidates to cleave ceruloplasmin into a fragment that could potentially bind MPO epitope aa448-
459.    
Figure 3.5 Full length ceruloplasmin digested by various serine proteases 
 
Figure 3.5  Serine protease digestion of full length ceruloplasmin.  Ceruloplasmin was digested by plasmin, 
thrombin, chymotrypsin, urokinase and lysozyme to identify a fragment at ~50kD.  Full length ceruloplasmin 
can be observed in lane 6 at ~150kD.  Proteases: plasmin, thrombin and urokinase were chosen for further 
analysis. 
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 Figure 3.6 shows the specificity of the enzymatic cleavage product of CP to block 
autoantibody binding. Ig samples from a vasculitis patient diagnosed with ANCA-negative 
glomerulonephritis (who were identified as reactive for MPO epitope aa448-459) and an MPO-
ANCA positive patient sample were assayed to observe the effect of the CP fragment on autoantibody 
reactivity.   Neither full length ceruloplasmin nor ceruloplasmin cleaved by thrombin successfully 
inhibited the autoantibody to bind MPO epitope aa448-459(Fig. 3.6A and B).   In contrast, both 
fragments of ceruloplasmin cleaved by either urokinase or plasmin preferentially bound epitope 
aa448-459 and inhibited autoantibody binding (Fig. 3.6C and D).  These results indicate the dominate 
species of ceruloplasmin bound to peptide aa448-459 was a cleavage product of full length 
ceruloplasmin.   
Figure 3.6 Specific ceruloplasmin fragment blocks autoantibody binding on native MPO 
 
Figure 3.6   Inhibition of autoantibody binding to MPO epitope aa448-459 by addition of Ceruloplasmin.  Full 
length CP (A), CP cleaved by thrombin (B) did not inhibit binding whereas the addition of CP cleaved by 
plasmin (C) and CP cleaved by urokinase (D) significantly inhibited binding.
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We hypothesize that some patients with ANCA-negative glomerulonephritis are unreactive to 
both clinical tests for ANCA disease (ELISA and IFA) because of a specific proteolytic fragment of 
ceruloplasmin normally present in sera which is blocking reactivity. These patients have a markedly 
restricted polyclonal response to MPO.  The antigen-specific ELISA used for clinical diagnosis is 
simulated in Figure 3.7A where the addition of the plasmin cleaved CP fragment blocks reactivity of 
seven sera samples from patients with ANCA-negative glomerulonephritis against native MPO.  The 
ELISA shows that with the addition of the specific epitope ‘blocker’ reactivity is inhibited which 
results in a false negative.  This phenomenon is not observed when using Ig from MPO-ANCA 
patients (n=4), as they have a polyclonal autoantibody response against native MPO.  The clinical 
diagnostic test utilizing indirect immunofluorescence may also provide a negative finding or an 
irregular staining pattern for patients deemed as ANCA-negative.  Could this be due to the presence 
of ceruloplasmin on the fixed neutrophils?   Using a polyclonal anti-ceruloplasmin antibody, an 
abundance of ceruloplasmin was detected which could be already bound to MPO at aa448-459 and 
therefore obscuring the autoantibody binding site (Fig. 3.7B).   
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Figure 3.7 Detection of anti-aa448-459 autoantibodies is obscured in clinical assays by a cleavage product 
of a common serum protein 
 
 
Figure 3.7   Panel A shows by ELISA that detection of anti-MPO 448-459 autoantibodies in total IgG from 
ANCA-negative patients (n=7) is muted by addition of cleaved ceruloplasmin (squares).   Due to the polyclonal 
nature of MPO-ANCA positive patients, the total Ig (n=4) (circles) reactivity appears unaffected by addition of 
ceruloplasmin.   Indirect Immunofluorescence staining (Panel B) shows that fixed neutrophils, when probed 
with anti-ceruloplasmin antibody, are positive for ceruloplasmin, explaining the negative IFA test of sera from 
ANCA-negative glomerulonephritis patients. 
 
The results presented in this chapter confirm that these eight patients diagnosed with ANCA-
negative glomerulonephritis are unreactive to one or both clinical tests for ANCA disease (ELISA 
and IFA) because of a proteolytic serum fragment indentified as ceruloplasmin which is able to 
specifically bind to native MPO at aa448-459 thereby masking the autoantibody binding site.    
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Clinical implications and biological significance 
The clinical implications of this discovery are far reaching.  Current treatment protocols rely 
on ANCA-positive tests, and therefore a false negative diagnostic test would have a detrimental 
impact on treatment decisions.  Understanding the intricate biology of autoimmune disease may help 
to further improve clinical testing, diagnosis and treatment.  Biologically, a serum component acting 
as a ‘blocking-factor’ binding to a known autoantigen raises the question of whether the body is 
actively making efforts to protect against autoimmunity, once tolerance is broken.  In the case of 
ANCA disease, the biological role of myeloperoxidase and its inhibitor ceruloplasmin (CP) and how 
they interact may give us clues to how aspects of autoimmunity can be regulated by the human body.  
Therefore, based on these results we hypothesize that MPO epitope aa448-459 is a pathogenic site on 
MPO and a specific ceruloplasmin fragment binds this site to protect from autoantibody binding. 
The interaction between CP and MPO has been studied in MPO-ANCA glomerulonephritis in 
relation to disease activity.  The initial theory was that patients who were diagnosed with ANCA 
disease were deficient in ceruloplasmin.  A ceruloplasmin deficiency or aceruloplasminemia, is 
marked by diabetes mellitus and retinal and neurodegeneration caused by a disruption of iron 
homeostasis
65
.  This hypothesis predicted that low levels of ceruloplasmin would be insufficient for 
the inhibition of MPO to produce hypocholorus acid which in excess would cause severe endothelial 
damage when neutrophils released copious amounts of MPO after activation by ANCA.  
First characterized by Segelmark et. al., CP and MPO were reported to have a physical 
interaction under physiological conditions and CP was able to inhibit the peroxidase reaction of MPO 
in vitro
12
.  Upon the discovery of CP to inhibit MPO, MPO-ANCA weas determined to disrupt the 
binding of CP and MPO.  Griffin et. al. reported that ANCA had a greater affinity to MPO than CP 
and  were able to reverse the inhibition of MPO by CP
66
.  More evidence of the affect MPO-ANCA 
has on the CP-MPO complex was reported by Xu et. al. to showed that MPO-ANCA were able to 
influence the oxidative activity of MPO.  They reported a correlation between the oxidation activity 
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of MPO after binding MPO-ANCA which positively correlated with the level of ceruloplasmin 
binding MPO in the presence of MPO-ANCA
67
.   
Many studies have tried to correlate the serum levels of ceruloplasmin in patients with ANCA 
glomerulonephritis with disease activity in order to prove the initial hypothesis that CP levels in these 
patients would be decreased compared to healthy subjects.  A study done in 1999 by Ara et. al. 
assayed sera CP levels in 21 patients with ANCA glomerulonephritis and found that in active disease 
none of the patients had low CP protein levels and 57% of their cohort had higher than normal 
levels
68
.  A second study done in 2002 by Baskin et. al. assayed sera CP levels in 45 patients during 
both active disease and clinical remission
69
.  They reported that samples taken from patients during an 
active disease state had on average higher than normal levels of CP and in disease remission CP 
levels were normal.  Again zero patients had lower than normal levels of CP in either active or 
remittent disease. In all of these studies, the CP that was assayed for was full length ceruloplasmin of 
130kD or 151kD.   
There is no resolved crystal structure which reveals the exact location of where CP binds to 
MPO but Sokolov et. al. characterized the complex of CP and MPO by three separate methods
70
.  
Using electrophoresis, gel filtration and photon-correlation spectroscopy they determined that the 
normal plasma stoichiometry of these protein levels was 1MPO:2CP.  They hypothesized that two CP 
molecules bound to the exposed heavy chain of MPO.  If CP does indeed bind to the heavy chain of 
MPO, this would lend more credence to previous reports of MPO-ANCA ability to disrupt this 
interaction which we now know primarily target the heavy chain.  
Our results diverge with these finding because instead of ANCA inhibiting the MPO/CP 
complex, a proteolytic CP fragment is prohibiting the binding of an anti- aa448-459 autoantibody.  
Despite the contrast, if MPO epitope aa448-459 is an autoantigenic site it is plausible, in order to 
protect against ANCA, for the body to produce more CP for the goal of generating more of the CP 
fragment to block the binding of a pathogenic autoantibody.  We do not know what the affect this 
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would have on the function of MPO.  We have uncovered that both full length CP and a CP fragment 
bind MPO epitope aa448-459 but only the fragment is able to compete for binding in the presence of 
MPO-ANCA.  The binding site, which is the epitope, can be seen on the crystal structure of MPO 
(Fig. 3.8). 
 
 
Figure 3.8  Myeloperoxidase crystal structure shown as a monomer.  Predicted glycosylation residues are 
shown in pink spheres with a multi-color heme in the center of the molecule.  MPO epitope 448-459 is shown in 
green. 
Figure 3.8 Ceruloplasmin fragment binding site of MPO epitope aa448-459 
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This observation suggests the existence of a positive feedback loop of an important CP 
fragment after an unexpected release of MPO to prevent endothelial damage by MPO byproducts, yet 
we know CP levels do not correlate with decreased disease severity.  This begs the question: Do 
patients with MPO-ANCA have a SNP in ceruloplasmin that makes this fragment non-functional or 
unable to bind MPO epitope aa448-459?  There are numerous SNPs found in CP and MPO that have 
been validated and result in a change in the amino acid sequence.  However, there are no studies 
connecting these known SNPs to ANCA disease.  None of the known SNPs found in MPO results in 
an amino acid change within the MPO epitope aa448-459.  With new data implicating a new role of a 
ceruloplasmin fragment, it is important to further study the known SNPs in CP and whether they play 
a role in proteolytic cleavage or MPO binding.  Uncovering a deficiency in function of CP or its 
cleavage enzyme may be an important aspect of the pathogenicity of ANCA. The data presented in 
this chapter brings to the forefront future directions to examine ceruloplasmin and its function in 
ANCA disease.  
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SUMMARY 
 
This body of work focuses on the specificity of autoantibody-antigen interactions and how 
differences in autoantibody binding sites (epitopes) impact disease.  In Chapter 1, while LAMP-2 was 
not identified as an important autoantigen specific to ANCA disease, we were able to uncover 
autoantigenic sites on MPO.  Little may be gleaned, from the clinical perspective, pertaining to the 
ability to predict remission and relapse in MPO-ANCA glomerulonephritis using autoantibody titer. 
Efforts in epitope mapping anti-MPO-autoantibodies using peptide libraries and chimeric molecules 
have been previously reported, and together have failed to uncover an immunodominant epitope.
20, 22, 
24
  
Our data in Chapter 2, illustrates that the majority (16/18) of disease associated anti-MPO-
autoantibodies are dependent on conformational structures for successful binding. MPO epitopes 
aa516-524 and aa448-459, which are both found exclusively in ANCA disease, correlate with disease 
activity. Further, when B6 mice were immunized with a T cell epitope, overlapping with the B cell 
epitope aa448-459, the mice mounted an autoantibody response similar to an active ANCA patient. 
Chapter 3 describes how MPO epitope aa448-459 was found to be blocked by a specific cleavage 
product of ceruloplasmin by a blood clotting factor.
12, 71
 Once ceruloplasmin was removed, sera from 
some patients diagnosed as ANCA-negative were reactive to MPO, specifically epitope aa448-459.  
The specificity of the autoantibody autoantigen interaction could be responsible for differences in 
disease expression, and may explain why clinical tests developed for autoantibody detection do not 
correlate with disease activity.
35, 64
 
 The mass spectrometry based method presented in this study is drastically more sensitive 
than current clinical testing and has uncovered extremely low titer MPO epitopes found in healthy 
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subjects as well as specific epitopes that correlate with disease activity. The utility of a more sensitive 
method to monitor patient epitope profiles over their disease course would not only enable more 
accurate diagnostics but also the ability to predict clinical outcomes based on the appearance of 
pathogenic autoantibodies possibly preventing organ damage.  
 
 
 
  
EPILOGUE 
THE ROLE OF ANCA IN GLOMERULONEPHRITIS: DISEASE 
DIAGNOSIS, PROGNOSIS AND TREATMENT 
Insight into the origin of ANCA disease 
In the past several years, the theory of molecular mimicry in GPA has resurfaced as a 
possible resolution to the question of the origin of ANCA.  The mechanism whereby infectious agents 
cause a compromise in immune tolerance leading to generation of self-reactive antibodies remains 
speculative. Taking into account the many purported theoretical possibilities from numerous research 
groups, molecular mimicry remains the main postulated mechanism 
72-74
.  According to this 
hypothesis, a susceptible
 
host acquires an infection with an agent that
 
is immunologically similar to 
the host antigens but differs
 
sufficiently to induce an immune response when presented to
 
T cells. As 
a result, tolerance to autoantigens breaks down,
 
and the pathogen-specific antibody cross-reacts with 
host structures to cause tissue damage and
 
disease.  Although LAMP-2 autoantibodies were not 
specific for ANCA disease, they were found in individuals with UTI infections which lends credence 
to the theory of molecular mimicry through cross reaction with a bacterial protein FimH.  A similar 
hypothesis can be made concerning MPO epitopes. Disease associated immunodominant MPO 
epitopes could mimic the sequence of a foreign antigen, bacterial or viral, and be responsible for 
triggering disease in susceptible individuals.   
Implications in the field of autoimmunity 
The data in this dissertation presents a novel utility for proteomics in autoimmune disease.  
The obvious next step is to determine the disease associated epitopes relevant in PR3-ANCA.  We 
have begun to use the same MS epitope excision approach to map anti-PR3 autoantibody specificity 
and have encountered many complications.  PR3 is an autocatalytic protein which can cleave itself as 
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well as autoantibodies, and the use of an inhibitor or recombinant PR3 diminishes the accuracy of 
results compared to the use of native protein.  Also, PR3 does not have ideal enzymatic cleavage sites 
which are essential for MS analysis. Given the numerous caveats in generating studying human PR3-
ANCA epitope profiles, further investigation will build the current knowledge base of epitope 
mapping in PR3-ANCA disease. 
The ability to uncover conformationally dependent disease associated epitopes is not only 
valuable to ANCA disease but to other antibody mediated autoimmune diseases as well.  For many 
years the pathogenic epitopes of a debilitating skin disease, pemphigus foliaceus (PF), have been 
sought after.  PF causes spontaneous cutaneous blistering on the epidermis as the result of IgG 
targeting the cell surface of keratinocytes, specifically one of the desmosomal cadherins, desmoglein 
1
75
.  Autoantibodies targeting desmoglein 1 disrupt cell-cell adhesion through an unknown 
mechanism.  Efforts to uncover the pathogenic epitopes of desmoglein utilizing overlapping peptide 
arrays have been unsuccessful thus requiring immunoblotting to assay reactivity
76
.  All epitopes 
targeted by autoantibodies were determined to be conformationally dependent.  PF is an excellent 
candidate for analysis by MS epitope excision because of the known autoantibody specificity and 
favorable properties of desmoglein 1. 
This technique can also be used to identify autoantigens in diseases long thought to be 
autoimmune in nature, including two common kidney diseases--minimal change disease (MCD) and 
focal segmental glomerulosclerosis (FSGS).   These diseases affect podocyte architecture and thus the 
ability of the glomerular filter to prevent urinary protein loss. These podocytopathies are believed by 
many to lie along a continuum, with MCD reversed by immunosuppression, whereas the changes of 
FSGS develop into irreversible scar.  Investigators since the 1970's have believed MCD to be 
immunologic in origin, yet it's pathogenesis is still poorly understood
77
.  Ninety percent of children 
with idiopathic nephrotic syndrome have MCD. Electron microscopy of kidney biopsies reveals 
diffuse effacement of podocyte foot processes, the clinical effect of which is dramatic proteinuria.  No 
87 
 
immune deposits or cellular infiltrate are seen by light microscopy
77
. Our hypothesis is that MCD is 
caused by development of autoantibodies against a circulating leukocyte (rather than tissue) which 
releases toxic cytokines damaging the podocytes.  MS epitope excuision is useful to test this 
hypothesis by 'fishing' for autoantigens in patient's serum and leukocyte lysates. Uncovering 
autoantigens is essential for defining the pathogenesis of autoimmune diseases, allowing for precise 
diagnosis and therapy.   
Potential for improvement on current therapies 
Current treatments for autoimmune diseases center around the same immunosuppression 
options used in various cancer or anti-organ rejection therapies.  Drugs like cyclosporine, steroids, 
and more recently rituximab have been used to eliminate the immune cells thought to be responsible 
for autoimmunity.  The same risk of secondary infection holds for patients with autoimmune disease 
who are treated with immunosuppression.  While their immune system is disabled, their disease 
progression arrests but for many patients upon the return of their B and T cells, relapse occurs.  In 
order to manipulate the immune system in patients suffering from autoimmune diseases, Stienman et. 
al. purpose an idea called inverse vaccination in order to eliminate specific B cell and T cell 
responses and reduce the risk of nonspecific immunosuppression
78
.  Researchers have successfully 
created a vaccine for multiple sclerosis (MS) in mice which targets autoantibody binding sites on 
myelin.  Stienman et. al reported that the DNA based vaccines were able to tolerize mice against 
particular sites on myelin after their first episode of paralysis and reduce or eliminate relapses.  These 
studies have translated to human phase I and II clinical trials with patients diagnosed with MS and 
have yielded promising results.  The identification of pathogenic epitopes on MPO could be used for 
not only disease profiling but potential therapies not unlike the idea of an inverse vaccine.  Peptide or 
protein treatments could be used to tolerize patients to autoantigenic epitopes.  Drugs that target 
certain B cell clones or better timing of immune therapy may save patients from unnecessary 
immunosuppression.   
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Another autoimmune disease that has had significant progress in the development of a 
vaccine is type 1 diabetes.  This is a disease in which autoantibodies target pancreatic islet cells 
causing the destruction of the only source of insulin in the body.  There is currently no cure or 
prevention of type 1 diabetes, only a life-long treatment of daily injections of recombinant insulin.  
Antigen specific immunotherapy is thought to be the best course of action to prevent or disrupt the 
autoimmune response in this disease
79
.  Type 1 diabetes usually develops in adolescence and 
therefore a vaccine which immunizes against the initial autoantigen (which is still under debate) could 
be enough to prevent the subsequent development of autoimmunity.  Vaccination of NOD mice with 
a single autoantigen or a disease associated epitope have been successful and have been translated to 
human clinical trials
79
.  Antigen specific immunotherapy and inverse vaccination are promising 
therapies that may enable prevention or someday even a cure for autoimmune diseases which 
autoantigens and pathogenic epitopes are known.  
Future directions 
Like any dissertation project there are many future directions to consider.  With the 
knowledge of disease associated MPO epitopes, a more sensitive clinical test can be developed not 
only for diagnosis but to monitor disease progression.  A method must be established to study 
conformational epitopes to determine the immunodominant epitope across disease populations.  
Translating human epitope profiles into animal models can also further the understanding of other 
disease factors such as: complement activation and the innate immune response in vivo.  
 Additional studies to pinpoint the role of a potentially protective ceruloplasmin fragment and 
how this fragment is functional or nonfunctional may play a role in disease severity.  The enzyme 
responsible for the cleavage of CP requires analysis of its serum levels and functionality in patients 
during active disease and clinical remission compared to healthy controls.  Once an epitope or 
inhibitor is determined, progress can be made to acquire better treatments or even prevention of 
ANCA disease. 
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Conclusions 
 
In the past decade, the field of antibody mediated autoimmune disease has made very slow 
progress in elucidating the origins of autoimmunity.  Equally important to discerning the cause of a 
break in self tolerance, is uncovering B cell epitope specificity.  The knowledge of autoantigenic 
epitopes is useful not only for diagnosis and treatment but also for the prevention of disease through 
vaccination. The importance of the site of autoantibody-autoantigen interaction is as essential to 
understanding disease pathogenesis as the existence of the autoantibodies themselves. 
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